Amedeo Smart

Free Medical Literature Service

 

Amedeo

Leukemia
  Free Subscription

Articles published in
Leuk Lymphoma
    November 2026
  1. DIAZ DE LA PINTA FJ, Torre-Castro J, Haro Ramos R, Arquero T, et al
    Perniosis-like lesions as an extramedullary manifestation preceding a chronic myelomonocytic leukemia diagnosis: a clinicopathological and molecular description.
    Leuk Lymphoma. 2026 Nov 5:1-4. doi: 10.1080/10428194.2026.2758498.
    >> Share

  2. MALAGOLA M, Castagna L, Avenoso D, Algeri M, et al
    Post-transplant maintenance in acute myeloid leukemia in Italy: results of the GITMO-maintenance survey.
    Leuk Lymphoma. 2026 Nov 3:1-5. doi: 10.1080/10428194.2026.2758497.
    >> Share

    October 2026
  3. CHEUNG CYM, Halim NAA, Gan GG, Wang Y, et al
    The APLC 2025 consensus recommendations on the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2026 Oct 30:1-19. doi: 10.1080/10428194.2026.2743349.
    >> Share

  4. MARCINEK A, Schweneker K, Meggendorfer M, Haferlach T, et al
    Acute promyelocytic leukemia with clonal hematopoiesis: a case study of APL in complete molecular remission transitioning to MDS/MPN and its clinical implications.
    Leuk Lymphoma. 2026 Oct 30:1-3. doi: 10.1080/10428194.2026.2755196.
    >> Share

  5. BANNATYNE J, Romon I, Dominguez JJ, Insunza A, et al
    Chronic myelomonocytic leukemia associated with lymphoid neoplasms.
    Leuk Lymphoma. 2026 Oct 30:1-5. doi: 10.1080/10428194.2026.2753811.
    >> Share

  6. CHING LJ, Wang CH, Lo WL, Cheng YJ, et al
    Single-Cell RNA sequencing analysis of cellular heterogeneity and microenvironment-driven signaling networks in acute myeloid leukemia.
    Leuk Lymphoma. 2026 Oct 29:1-18. doi: 10.1080/10428194.2026.2740252.
    >> Share

  7. ZEIDAN AM, Zhao R, Voegel A, Christensen D, et al
    Time burden and treatment patterns of patients with newly diagnosed acute myeloid leukemia receiving parenteral hypomethylating agents in combination with venetoclax.
    Leuk Lymphoma. 2026 Oct 28:1-10. doi: 10.1080/10428194.2026.2726604.
    >> Share

  8. GJERTSEN BT, Isaksen MY, Ktoridou-Valen I, Azrakhsh NA, et al
    Metronomic per oral decitabine-cedazuridine plus venetoclax in acute myeloid leukemia.
    Leuk Lymphoma. 2026 Oct 28:1-5. doi: 10.1080/10428194.2026.2740250.
    >> Share

  9. JIANG X, Zhang H, Miao Q, Wang Y, et al
    Secondary minimally differentiated acute leukemia with plasmacytoid dendritic cell differentiation (pDC-AML) following chemoradiotherapy for Ewing sarcoma in a child: biallelic EZH2 inactivation.
    Leuk Lymphoma. 2026 Oct 26:1-8. doi: 10.1080/10428194.2026.2751738.
    >> Share

  10. MACLEOD S, Desmond R, Browne C, Fatima A, et al
    Hairy cell leukemia associated haemophagocytic lymphohistiocytosis.
    Leuk Lymphoma. 2026 Oct 23:1-3. doi: 10.1080/10428194.2026.2747549.
    >> Share

  11. PATEL T, Shah N, Heyman B, Kipps T, et al
    Immunoglobulin kinetics and infection patterns across venetoclax-based regimens in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2026 Oct 20:1-12. doi: 10.1080/10428194.2026.2745238.
    >> Share

  12. KANNAN S, Jennings J, Hutchinson L, Higgins A, et al
    Oral azacitidine as time-limited, PCR-dependent maintenance in acute myeloid leukemia with inv(16): two case reports.
    Leuk Lymphoma. 2026 Oct 15:1-6. doi: 10.1080/10428194.2026.2747547.
    >> Share

  13. DE LA GARZA-SALAZAR F, Lankenau Vela DL, Munoz Cruz DG
    Clinical outcomes with azole and other CYP3A4 inhibitor coadministration during venetoclax plus azacitidine or decitabine therapy in newly diagnosed acute myeloid leukemia: a systematic review and meta-analysis.
    Leuk Lymphoma. 2026 Oct 7:1-17. doi: 10.1080/10428194.2026.2742608.
    >> Share

  14. ALHURAIJI A, Alshemmari S, Hamadah A, Jain N, et al
    Venetoclax consolidation deepens response and enables measurable residual disease-guided finite therapy in BTK inhibitor-treated chronic lymphocytic leukemia.
    Leuk Lymphoma. 2026 Oct 1:1-6. doi: 10.1080/10428194.2026.2741763.
    >> Share

  15. LIN RY, Tinajero J, Gu Z, Agrawal V, et al
    Clinical outcomes of adults with PAX5-mutated or rearranged B-cell acute lymphoblastic leukemia.
    Leuk Lymphoma. 2026 Oct 1:1-8. doi: 10.1080/10428194.2026.2740988.
    >> Share

  16. POKHARIYAL S, Chakraborty S, Arora S, Pal Singh P, et al
    Efficacy and safety of three-drug induction-based MASPORE 2003 chemotherapy protocol in standard- and intermediate-risk pediatric acute lymphoblastic leukemia: a decade-long single-center experience from India.
    Leuk Lymphoma. 2026 Oct 1:1-13. doi: 10.1080/10428194.2026.2739354.
    >> Share

    September 2026
  17. BORRAS-BLASCO J, Valcuende-Rosique A, Cornejo-Uixeda S
    Letter to the editor regarding 'Real-world venetoclax dosing patterns and treatment persistence in patients with acute myeloid leukemia: a community pharmacy database study in Japan'.
    Leuk Lymphoma. 2026 Sep 16:1-2. doi: 10.1080/10428194.2026.2732486.
    >> Share

  18. DAUNOV M
    Expanding access to leukemia specialists in the venetoclax era.
    Leuk Lymphoma. 2026 Sep 13:1-3. doi: 10.1080/10428194.2026.2731270.
    >> Share

  19. SCHOENBECK K, Wei D, Hazra NC, Constantinescu C, et al
    Adverse events, quality of life, and work impairment in patients with chronic myeloid leukemia (CML)-a survey of first- and second-line tyrosine kinase inhibitor (TKI) intolerance in the US.
    Leuk Lymphoma. 2026 Sep 13:1-11. doi: 10.1080/10428194.2026.2721033.
    >> Share

  20. PAPADAKI A, Baker R, Nacheva E, O'Nions J, et al
    Targeted RNA sequencing supports risk stratification and treatment decision-making in adolescents and young adult and adult patients with acute lymphoblastic leukemia: a UK single-center experience.
    Leuk Lymphoma. 2026 Sep 6:1-4. doi: 10.1080/10428194.2026.2726608.
    >> Share

  21. GOSHIMA Y, Saika T, Kado Y, Yamazaki M, et al
    Response to Borras-Blasco et al. regarding "Real-world venetoclax dosing patterns and treatment persistence in patients with acute myeloid leukemia: a community pharmacy database study in Japan".
    Leuk Lymphoma. 2026 Sep 6:1-2. doi: 10.1080/10428194.2026.2724604.
    >> Share

  22. FARAG CM, Mercurio A, Rouf R, Fried H, et al
    Revisiting invasive fungal infections in acute lymphoblastic leukemia: a systematic review and meta-analysis.
    Leuk Lymphoma. 2026 Sep 6:1-12. doi: 10.1080/10428194.2026.2724605.
    >> Share

  23. GARCIA JS, Desai P, Zeidner JF, Wolach O, et al
    Venetoclax and hypomethylating agents versus other therapies: an international, multicenter, retrospective cohort chart review study.
    Leuk Lymphoma. 2026;67:2282-2294.
    >> Share

  24. VEY N, Salamero O, Bajel A, Montesinos P, et al
    Phase 1 clinical trial of S64315, an intravenous MCL1 inhibitor, in patients with myeloid malignancies.
    Leuk Lymphoma. 2026;67:2305-2312.
    >> Share

    August 2026
  25. ACHARYA S, Chauhan R, Dass J, Kv VB, et al
    MLLT10 rearranged acute leukemia-finding order in ambiguity-a case series from a North Indian tertiary care center.
    Leuk Lymphoma. 2026 Aug 26:1-4. doi: 10.1080/10428194.2026.2719275.
    >> Share

  26. XIE Y, Ng I, Liu Y, Wang H, et al
    The roles of RUNX1 in megakaryocyte differentiation in myeloid leukemia.
    Leuk Lymphoma. 2026 Aug 24:1-11. doi: 10.1080/10428194.2026.2718439.
    >> Share

  27. VON LUCADOU M, Burbaum LC, Marklin M, Heitmann JS, et al
    Soluble PD-L1 as prognostic biomarker in acute myeloid leukemia.
    Leuk Lymphoma. 2026 Aug 18:1-9. doi: 10.1080/10428194.2026.2707891.
    >> Share

  28. DEANGELO DJ, Chen Y, Cassaday RD, Hibma JE, et al
    Dose optimization of single-agent inotuzumab ozogamicin in adults with relapsed/refractory acute lymphoblastic leukemia.
    Leuk Lymphoma. 2026 Aug 18:1-11. doi: 10.1080/10428194.2026.2714343.
    >> Share

  29. UYEMURA B, Hollnagel F, Hall A, Brunner M, et al
    Impact of Area Deprivation Index in patients with newly diagnosed acute myeloid leukemia treated with a venetoclax-based regimen: a single-center retrospective study.
    Leuk Lymphoma. 2026 Aug 16:1-8. doi: 10.1080/10428194.2026.2711591.
    >> Share

  30. SOBON A, Iskierka-Jazdzewska E, Drozd-Sokolowska J, Pula A, et al
    Efficacy and tolerability of venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukemia - real-world analysis of Polish adult leukemia study group.
    Leuk Lymphoma. 2026 Aug 10:1-10. doi: 10.1080/10428194.2026.2690480.
    >> Share

  31. BRONSTEIN Y, Rokach L, Herishanu Y, Arbel R, et al
    Prognostic significance of baseline liver enzyme patterns in chronic lymphocytic leukemia: a nationwide real-world cohort study.
    Leuk Lymphoma. 2026 Aug 9:1-12. doi: 10.1080/10428194.2026.2711592.
    >> Share

  32. OZAKI S, Miyao K, Yamamoto S, Wakayama T, et al
    Fatal differentiation syndrome-associated myocarditis caused by PML: RARalpha-positive neutrophils in acute promyelocytic leukemia.
    Leuk Lymphoma. 2026 Aug 6:1-3. doi: 10.1080/10428194.2026.2714599.
    >> Share

  33. NARKHEDE MS, Blau S, Peevyhouse A, Neuhalfen H, et al
    Hypertension and time to treatment failure with acalabrutinib and ibrutinib in treatment-naive CLL/SLL.
    Leuk Lymphoma. 2026;67:2106-2115.
    >> Share

  34. MURPHY DJ, El Hussein S, Applebee A, Thomas A, et al
    Chimeric antigen receptor T-cell therapy induces complete remission in a patient with concurrent CLL with CNS involvement and multiple sclerosis.
    Leuk Lymphoma. 2026;67:2057-2063.
    >> Share

    July 2026
  35. ONAKA T, Imada K
    Clinical considerations associated with CPX-351 therapy for high-risk acute myeloid leukemia.
    Leuk Lymphoma. 2026 Jul 25:1-4. doi: 10.1080/10428194.2026.2704267.
    >> Share

  36. GLAIT SANTAR C, Katz BZ
    Philadelphia-negative B-cell acute lymphoblastic leukemia developing after treatment for multiple myeloma: a case report.
    Leuk Lymphoma. 2026 Jul 22:1-4. doi: 10.1080/10428194.2026.2693916.
    >> Share

  37. FEDOROV K, Naranjo M, Esplund J, Leidy S, et al
    FLAG-Ida-venetoclax in acute myeloid leukemia: real-world efficacy and the impact of venetoclax duration on outcomes.
    Leuk Lymphoma. 2026 Jul 15:1-5. doi: 10.1080/10428194.2026.2700469.
    >> Share

  38. MINA A, Xu Y, Kapustyan TA, Dhalla M, et al
    Treatment inequity among older adults with newly diagnosed acute myeloid leukemia ineligible for intensive therapy.
    Leuk Lymphoma. 2026 Jul 12:1-9. doi: 10.1080/10428194.2026.2691911.
    >> Share

  39. TAN L, Wang X, Zhao Y, Li J, et al
    Glofitamab for the treatment of relapsed/refractory hairy cell leukemia: a case report.
    Leuk Lymphoma. 2026 Jul 6:1-4. doi: 10.1080/10428194.2026.2689467.
    >> Share

  40. ORVAIN C, Othus M, Byelykh M, Schoch G, et al
    Pre- and post-transplant serum albumin levels and outcomes after allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia.
    Leuk Lymphoma. 2026 Jul 6:1-13. doi: 10.1080/10428194.2026.2695317.
    >> Share

  41. TIBIRICA DOS REIS D, Silvestri EF, Farah de Oliveira EJ, Chiedde M, et al
    Leukemia mortality analysis in the pediatric population in Sao Paulo state, Brazil, 2000-2019.
    Leuk Lymphoma. 2026 Jul 5:1-9. doi: 10.1080/10428194.2026.2691908.
    >> Share

  42. GAO B, Yan W, Xue J, Zhang S, et al
    MBP1 inhibits AML proliferation through downregulating noncanonical Wnt/Ca(2+) signaling pathway.
    Leuk Lymphoma. 2026;67:1749-1759.
    >> Share

    June 2026
  43. HOLOPAINEN A, Lehto HR, Kuittinen T, Nuutinen M, et al
    Specialist palliative care access and end-of-life hospitalizations in acute leukemia: a nationwide register study.
    Leuk Lymphoma. 2026 Jun 26:1-9. doi: 10.1080/10428194.2026.2690477.
    >> Share

  44. POMERANTZ LD, Rabe KG, Hampel PJ, Roeker LE, et al
    Overall survival of patients with chronic lymphocytic leukemia treated with venetoclax-obinutuzumab compared to age- and sex-matched general population.
    Leuk Lymphoma. 2026 Jun 25:1-5. doi: 10.1080/10428194.2026.2687633.
    >> Share

  45. MOLICA S, Giannarelli D, Allsup D
    An indirect comparison of pirtobrutinib with second-generation covalent Bruton tyrosine kinase inhibitors in BTKi naive, and relapsed-refractory chronic lymphocytic leukemia: results of a network meta-analysis.
    Leuk Lymphoma. 2026 Jun 21:1-8. doi: 10.1080/10428194.2026.2690478.
    >> Share

  46. SETH N, Deb PQ, Tam W
    KRAS-mutated clonal hematopoiesis gives rise to lineage-divergent B-lymphoblastic leukemia/lymphoma and persistent post-therapy monocytosis.
    Leuk Lymphoma. 2026 Jun 21:1-5. doi: 10.1080/10428194.2026.2689470.
    >> Share

  47. RUI J, Gao R, Shen Y, Wu D, et al
    Efficacy of allogeneic haematopoietic stem cell transplantation in acute myeloid leukemia with myelodysplasia-related genetics.
    Leuk Lymphoma. 2026 Jun 18:1-9. doi: 10.1080/10428194.2026.2687634.
    >> Share

  48. LEVY YURKOVSKI I, Sharf G, Koren L, Tadmor T, et al
    Shared decision-making, treatment priorities and communication gaps in chronic lymphocytic leukemia: an Israeli national survey.
    Leuk Lymphoma. 2026 Jun 16:1-8. doi: 10.1080/10428194.2026.2687629.
    >> Share

  49. FRADIN JJ, Rein L, Szabo A, Carlson KS, et al
    Real-world treatment and outcomes in hairy cell leukemia: a multicenter retrospective cohort including BRAF inhibitor therapy.
    Leuk Lymphoma. 2026 Jun 11:1-9. doi: 10.1080/10428194.2026.2684259.
    >> Share

  50. ALHAJAHJEH A, Beke KE, Grimshaw AA, Aguirre LE, et al
    Menin inhibitors for patients with relapsed/refractory acute myeloid leukemia (AML): a systematic review and meta-analysis.
    Leuk Lymphoma. 2026 Jun 7:1-13. doi: 10.1080/10428194.2026.2682397.
    >> Share

  51. LEVY YURKOVSKI I, Kreiniz N, Peleg-Nesher S, Koren L, et al
    Sexual health and intimacy concerns among patients with chronic lymphocytic leukemia: a cross-sectional needs assessment study.
    Leuk Lymphoma. 2026 Jun 5:1-9. doi: 10.1080/10428194.2026.2682282.
    >> Share

  52. TADMOR T, Levy Yurkovski I, Kreiniz N, Gorenberg M, et al
    FDG PET-CT in hairy cell leukemia: defining standard metabolic uptake across disease compartments.
    Leuk Lymphoma. 2026 Jun 3:1-4. doi: 10.1080/10428194.2026.2682291.
    >> Share

  53. GOTETI S, Kim MS, Cai J, Hayes-Lattin B, et al
    Lineage switch from T- ALL to a clonal related T/myeloid leukemia following treatment with CD38 directed therapy.
    Leuk Lymphoma. 2026 Jun 1:1-4. doi: 10.1080/10428194.2026.2654779.
    >> Share

    May 2026
  54. HORSCH L, Baron J, Sung PJ, Wang ES, et al
    Management and risk mitigation strategies for FLT3-ITD+ acute myeloid leukemia: clinical utilization of quizartinib.
    Leuk Lymphoma. 2026 May 30:1-8. doi: 10.1080/10428194.2026.2676107.
    >> Share

  55. AGARWAL G, Tonk RK, Sangwan K
    Emerging drug profile: menin inhibitors in NPM1-mutated and KM2A-rearranged acute myeloid leukemia.
    Leuk Lymphoma. 2026 May 27:1-17. doi: 10.1080/10428194.2026.2674818.
    >> Share

  56. GOSHIMA Y, Saika T, Kado Y, Yamazaki M, et al
    Real-world venetoclax dosing patterns and treatment persistence in patients with acute myeloid leukemia: a community pharmacy database study in Japan.
    Leuk Lymphoma. 2026 May 22:1-8. doi: 10.1080/10428194.2026.2665793.
    >> Share

  57. SHAO H, Dong N, Shao R, Sokol L, et al
    Flow cytometric analysis of phenotypes and naive/memory/effector T-cell subsets of T-cell large granular lymphocytic leukemia.
    Leuk Lymphoma. 2026 May 13:1-10. doi: 10.1080/10428194.2026.2667487.
    >> Share

  58. SALAH T, Stahl M, Bewersdorf JP
    Metabolic dysfunction-associated steatotic liver disease and acute leukemias - a literature review and future directions.
    Leuk Lymphoma. 2026;67:1221-1230.
    >> Share

    April 2026
  59. LEGG A, Lambova A, Ralphs E, Keapoletswe K, et al
    The maturing picture of CPX-351 in acute myeloid leukemia: long-term real-world experience with CPX-351 treatment for acute myeloid leukemia in England.
    Leuk Lymphoma. 2026 Apr 28:1-5. doi: 10.1080/10428194.2026.2656725.
    >> Share

  60. PELLAND-MARCOTTE MC, Ethier C, Manirakiza A, Perrault H, et al
    Asparaginase activity levels and toxicity in children and adolescents with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2026 Apr 25:1-8. doi: 10.1080/10428194.2026.2656726.
    >> Share

  61. MARCINEK A, Huber S, Hutter S, Meggendorfer M, et al
    Defined genetic abnormalities shape the clonal hierarchy in acute myeloid leukemia as founding events.
    Leuk Lymphoma. 2026 Apr 21:1-4. doi: 10.1080/10428194.2026.2659222.
    >> Share

  62. MARKOSIAN C, Buckley CW, Chai-Ho W, Schiller GJ, et al
    Differential responses to sequential menin inhibitor therapy for acute leukemia underscore the complexities of acquired resistance.
    Leuk Lymphoma. 2026 Apr 15:1-4. doi: 10.1080/10428194.2026.2656727.
    >> Share

  63. MAJRASHI A, Shantsila A, Gue YX, Williams S, et al
    Effect of age and sex on cardiovascular outcomes among patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitors: a propensity matched analysis.
    Leuk Lymphoma. 2026 Apr 11:1-11. doi: 10.1080/10428194.2026.2653123.
    >> Share

  64. MICHAELS-IGBOKWE C, Lu H, Winfree KB, Bhandari NR, et al
    Treatment choice for chronic lymphocytic leukemia after covalent BTKi therapy: a patient and oncologist preference study.
    Leuk Lymphoma. 2026 Apr 10:1-13. doi: 10.1080/10428194.2026.2648867.
    >> Share

  65. MOHTY R, Narra R, Mims AS, Hunter C, et al
    Predictors of complete molecular response and impact of allogeneic hematopoietic stem cell transplantation on outcome in patients with Philadelphia chromosome positive acute lymphoblastic leukemia (ALL): results from the Consortium on Myeloid Malignan
    Leuk Lymphoma. 2026 Apr 9:1-8. doi: 10.1080/10428194.2026.2650679.
    >> Share

  66. NAKAMURA D, Ueno T, Nakabeppu SI, Shyodai A, et al
    Validation of prognostic indices in adult T-cell leukemia/lymphoma and their prognostic value at the start of second-line treatment.
    Leuk Lymphoma. 2026 Apr 1:1-7. doi: 10.1080/10428194.2026.2645946.
    >> Share

  67. LEVY YURKOVSKI I, Schiff E, Attias S, Sharf G, et al
    Use of dietary and herbal supplements and communication with hematologists regarding such use among patients with CLL: a national survey.
    Leuk Lymphoma. 2026;67:1080-1087.
    >> Share

    March 2026
  68. CRODEN J, Garcia-Manero G, Chien K, DiNardo C, et al
    A phase I open label study of fostamatinib, a SYK inhibitor, in patients with lower-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.
    Leuk Lymphoma. 2026 Mar 30:1-7. doi: 10.1080/10428194.2026.2650674.
    >> Share

  69. MERRILL M, Kim HT, Kelkar AH, Panaro K, et al
    Allogeneic transplant outcomes in T-cell prolymphocytic leukemia: a single-center retrospective study.
    Leuk Lymphoma. 2026 Mar 30:1-7. doi: 10.1080/10428194.2026.2645933.
    >> Share

  70. PUSTAKE M, Odeh J, Harisingani A, Khosla A, et al
    Temporal improvements in survival with persistent disparities in acute myeloid leukemia: a two-decade population-based analysis from the United States.
    Leuk Lymphoma. 2026 Mar 30:1-14. doi: 10.1080/10428194.2026.2643750.
    >> Share

  71. LEVY V, Lengline E, Chevret S
    When evaluating targeted therapies in chronic lymphocytic leukemia, the absolute measure of treatment effect should be preferred.
    Leuk Lymphoma. 2026 Mar 24:1-10. doi: 10.1080/10428194.2026.2647950.
    >> Share

  72. SIMON F, Ligtvoet R, Furstenau M, Langerbeins P, et al
    Censoring imbalances in randomized first-line trials of chronic lymphocytic leukemia.
    Leuk Lymphoma. 2026 Mar 17:1-7. doi: 10.1080/10428194.2026.2634939.
    >> Share

  73. GUOLO F, Del Sette P, Riccardi F, Ballerini F, et al
    Like a bolt from the blue: the trauma of facing acute leukemia and lymphoma diagnosis and its clinical implications.
    Leuk Lymphoma. 2026 Mar 7:1-7. doi: 10.1080/10428194.2026.2634180.
    >> Share

  74. SIMKHADA S, Acharya L, Loeffler B, Ravindra A, et al
    Improved overall survival in acute myeloid leukemia over the last 15 years.
    Leuk Lymphoma. 2026 Mar 7:1-9. doi: 10.1080/10428194.2026.2635662.
    >> Share

  75. HOFSTETTER L, Shimony S, Sherban A, Raanani P, et al
    Pericardial effusion and tamponade as a rare cardiac toxicity of covalent BTK inhibitors in CLL-a multi-modality study.
    Leuk Lymphoma. 2026;67:860-867.
    >> Share

  76. CHAUHAN A, Singh K, Chaturvedi CP, Rai AK, et al
    BET bromodomain inhibition: a potential therapeutic avenue in MEF2D-HNRNPUL1-rearranged B-cell acute lymphoblastic leukaemia.
    Leuk Lymphoma. 2026;67:868-879.
    >> Share

  77. FLEROVA E, Chai J, Choudhuri J, Gong JZ, et al
    Correlation of EZH2 and related signaling molecules p-STAT3, p-ERK1/2, and MYC overexpression with H3K27 trimethylation associates differently to disease progression in JAK2 mutation -positive and -negative myeloid neoplasms.
    Leuk Lymphoma. 2026;67:832-845.
    >> Share

    February 2026
  78. TIAN JX, Liao YX, Wang XX, Wang XD, et al
    Olverembatinib and high-dose methotrexate in acute lymphoblastic leukemia: delayed methotrexate clearance and increased nephrotoxicity.
    Leuk Lymphoma. 2026 Feb 25:1-7. doi: 10.1080/10428194.2026.2634179.
    >> Share

  79. REDDY NALLA A, Ganesan K, Muthukumar V, Seshadri N, et al
    Short, safe, and sustainable: outpatient blinatumomab as a bridge and beyond in children with pre B-acute lymphoblastic leukemia.
    Leuk Lymphoma. 2026 Feb 24:1-3. doi: 10.1080/10428194.2026.2634943.
    >> Share

  80. MAQBOOL S, Rehman MEU, Khan I, Ibrahim M, et al
    Survival disparities in Philadelphia chromosome-positive vs. Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia in the era of modern therapeutic approaches: a decade-long surveillance, epidemiology, and end results (SEER) data based
    Leuk Lymphoma. 2026 Feb 23:1-8. doi: 10.1080/10428194.2026.2621822.
    >> Share

  81. OHNO H, Maekawa F, Hayashida M, Nakagawa M, et al
    t(14;19)(q32;q13) breakpoints telomeric to BCL3 on 19q13.32 in B-cell lymphomas other than chronic lymphocytic leukemia and long-range structures of der(19)t(14;19) based on optical genome mapping.
    Leuk Lymphoma. 2026 Feb 22:1-11. doi: 10.1080/10428194.2026.2633186.
    >> Share

  82. DYMOCK SCC, Oommen J, Malinge S, Cheung LC, et al
    Menin inhibitors display differential in vitro sensitivity in KMT2A-rearranged infant acute lymphoblastic leukemia.
    Leuk Lymphoma. 2026 Feb 19:1-5. doi: 10.1080/10428194.2026.2631099.
    >> Share

  83. HUGHES EE, Baron J, Wang ES, Yu H, et al
    Mini-HyperCVD in secondary acute lymphoblastic leukemia following multiple myeloma treatment from lenalidomide: a case series.
    Leuk Lymphoma. 2026 Feb 17:1-4. doi: 10.1080/10428194.2026.2631107.
    >> Share

  84. CLAIBORNE JP, Tsai HL, Ghiaur G, Smith BD, et al
    Chemotherapy regimens with second generation tyrosine kinase inhibitors for BCR-ABL B-cell acute lymphoblastic leukemia: comparative outcomes and role of allogeneic hematopoietic cell transplantation.
    Leuk Lymphoma. 2026 Feb 15:1-14. doi: 10.1080/10428194.2026.2628206.
    >> Share

  85. AHMED VR, Rahman FM
    NOTCH1 and SF3B1 mutations in chronic lymphocytic leukemia with their clinical associations.
    Leuk Lymphoma. 2026 Feb 14:1-8. doi: 10.1080/10428194.2026.2626937.
    >> Share

  86. LI B, Chen Y, Chen S, Zheng Z, et al
    Risk prediction model and survival analysis of adult patients with intracranial hemorrhage in acute leukemia.
    Leuk Lymphoma. 2026 Feb 11:1-10. doi: 10.1080/10428194.2026.2624658.
    >> Share

  87. CUI D, Tao Y, Zhang Y, Luo J, et al
    Clinical characteristics and treatment outcomes of pediatric Philadelphia chromosome positive acute lymphoblastic leukemia: a comparative analysis of p190 and p210 subtypes in the TKI era.
    Leuk Lymphoma. 2026 Feb 8:1-8. doi: 10.1080/10428194.2026.2624661.
    >> Share

  88. TAN KW, Xu Y, Huang YH, Qiu QC, et al
    Coexistence of BCR::ABL1 with IKZF1::ETV6 fusion in an adult patient with acute B-lymphoblastic leukemia.
    Leuk Lymphoma. 2026 Feb 3:1-5. doi: 10.1080/10428194.2026.2621828.
    >> Share

  89. O'BRIEN J, Tomlinson B, Patel MJ, Van Besien K, et al
    ATRA treatment in the emergency department is associated with reduced early mortality in acute promyelocytic leukemia-a real-world multicenter retrospective cohort analysis.
    Leuk Lymphoma. 2026 Feb 3:1-9. doi: 10.1080/10428194.2026.2623196.
    >> Share

  90. YOSHIDA K, Mushino T, Tanaka K, Kosako H, et al
    Distribution of CD30-positive tumor cell proportions in adult T-cell leukemia/lymphoma.
    Leuk Lymphoma. 2026 Feb 3:1-5. doi: 10.1080/10428194.2026.2622526.
    >> Share

  91. HERSTEIN JE, Marx KR, Haddad FG, Chien KS, et al
    Case series: rhabdomyolysis in patients taking isocitrate dehydrogenase inhibitors for myelodysplastic syndrome and relapsed/refractory acute myeloid leukemia.
    Leuk Lymphoma. 2026 Feb 2:1-3. doi: 10.1080/10428194.2026.2621831.
    >> Share

    January 2026
  92. CHUMNUMSIRIWATH P, Kongtim P, Lipan L, Jercan CG, et al
    Efficacy of CD19 CAR T-cell therapy for patients with B-cell acute lymphoblastic leukemia relapsed after allogeneic transplantation.
    Leuk Lymphoma. 2026 Jan 22:1-4. doi: 10.1080/10428194.2026.2619496.
    >> Share

  93. JEFFREY A, Mason G, Coyle L, Mackinlay N, et al
    The spectrum of tonsillar involvement in chronic lymphocytic leukemia (CLL).
    Leuk Lymphoma. 2026 Jan 19:1-9. doi: 10.1080/10428194.2026.2616323.
    >> Share

  94. BLOMBERY P, McKeague S, Hartog B, Nguyen T, et al
    KRAS internal tandem duplications and alternative driver variants in BRAF Val600Glu negative hairy cell leukemia.
    Leuk Lymphoma. 2026 Jan 13:1-3. doi: 10.1080/10428194.2026.2615055.
    >> Share

  95. PULLANUR KARUMAMPURATH A, Errington A, Norman P, Hayes L, et al
    Patterns and trends in the incidence of leukemia in children and young adults in Northern England by age, sex, socioeconomic and urban-rural status.
    Leuk Lymphoma. 2026 Jan 13:1-7. doi: 10.1080/10428194.2025.2612236.
    >> Share

  96. HU GH, Zuo YX, Zhang XH, Wang Y, et al
    Efficacy and safety of inotuzumab ozogamicin as the definitive therapeutic option prior to allogeneic hematopoietic stem cell transplantation for pediatric relapsed/refractory B-cell acute lymphoblastic leukemia.
    Leuk Lymphoma. 2026 Jan 7:1-7. doi: 10.1080/10428194.2025.2611117.
    >> Share

  97. GUO J, Li M, Zhang L, Zhang Q, et al
    Clinical outcomes of modified busulfan plus cyclophosphamide versus total body irradiation plus cyclophosphamide for T-cell acute lymphoblastic leukemia/lymphoma.
    Leuk Lymphoma. 2026 Jan 5:1-14. doi: 10.1080/10428194.2025.2605516.
    >> Share

  98. LOPEZ-SANCHEZ C, van Bruggen JAC, Kater AP
    Tumor-associated disruption of T cell receptor signaling: lessons across cancers with implications for CLL.
    Leuk Lymphoma. 2026;67:306-314.
    >> Share

    December 2025
  99. OKA S, Ueda-Akagi Y, Mitsuyoshi T, Ono K, et al
    Reduced dose and shorter duration venetoclax regimens are effective for newly diagnosed acute myeloid leukemia patients not considered fit for intensive treatment.
    Leuk Lymphoma. 2025 Dec 25:1-6. doi: 10.1080/10428194.2025.2604566.
    >> Share

  100. HARADA K, Iwata S, Tomita S, Nasukawa M, et al
    Cord blood versus bone marrow/peripheral blood stem cell transplantation under reduced-intensity conditioning in high-risk acute myeloid leukemia and myelodysplastic syndromes.
    Leuk Lymphoma. 2025 Dec 25:1-13. doi: 10.1080/10428194.2025.2604565.
    >> Share

  101. STAFYLIDIS C, Lakiotaki E, Rougala N, Giannakopoulou N, et al
    Reclassifying T-cell lymphomas in human T-lymphotropic virus 1 carriers: a familial case of adult T-cell leukemia/lymphoma with diagnostic and pathogenetic implications.
    Leuk Lymphoma. 2025 Dec 25:1-5. doi: 10.1080/10428194.2025.2606948.
    >> Share

  102. SWAROOP A, Oh T, Wolniak K, Sukhanova M, et al
    Donor-derived acute myeloid leukemia after solid organ transplant: evidence for leukemic stem cell transmission.
    Leuk Lymphoma. 2025 Dec 23:1-4. doi: 10.1080/10428194.2025.2604563.
    >> Share

  103. LIU AJ, Batterham E, Nedumannil R, Ritchie D, et al
    Reduced burden of infection with consecutive day dosing of high dose cytarabine consolidation versus conventional dosing for acute myeloid leukemia.
    Leuk Lymphoma. 2025 Dec 18:1-13. doi: 10.1080/10428194.2025.2599991.
    >> Share

  104. ARNAUD I, Rodriguez-Contreras FV, Aguirre-Munoz VY, Pulido M, et al
    Vincristine dose adjustments in adult acute lymphoblastic leukemia: impact on treatment outcomes and neuropathy.
    Leuk Lymphoma. 2025 Dec 17:1-10. doi: 10.1080/10428194.2025.2604567.
    >> Share

  105. SANCHEZ JR 2ND, Liu C, Pawar V, Huang Y, et al
    NAMPT inhibition uncovers therapeutic vulnerabilities to venetoclax and chemotherapy in acute myelogenous leukemia.
    Leuk Lymphoma. 2025 Dec 16:1-11. doi: 10.1080/10428194.2025.2571199.
    >> Share

  106. HAZAR V, Makiya M, Yalcin K, Cadiu JT, et al
    Prognostic factors and survival outcomes of first CNS relapse in childhood acute lymphoblastic leukemia: results from the ALL-IC REL 2016 study.
    Leuk Lymphoma. 2025 Dec 16:1-7. doi: 10.1080/10428194.2025.2598861.
    >> Share

  107. ZHANG LN, Pan WW, Qu H, Li Z, et al
    Quercetin induces apoptosis and autophagy in pediatric acute lymphoblastic leukemia by regulating miR-367/KLF4/JNK signaling axis.
    Leuk Lymphoma. 2025 Dec 16:1-17. doi: 10.1080/10428194.2025.2601321.
    >> Share

  108. LI S, Chen G, Wang H, Guan W, et al
    Pre- and post-transplant extramedullary involvement in adult patients with t(8;21)(q22;q22) acute myeloid leukemia: incidence, risk factors and outcomes.
    Leuk Lymphoma. 2025 Dec 9:1-10. doi: 10.1080/10428194.2025.2598364.
    >> Share

  109. KUEK V, Kotecha RS, Cheung LC
    Beyond bone: the emerging role of osteoclasts in immune regulation, leukemia development and following myeloablative therapy.
    Leuk Lymphoma. 2025 Dec 4:1-15. doi: 10.1080/10428194.2025.2595220.
    >> Share

  110. PONNUSAMY U, Perumal V
    Comprehensive review on learning models of leukemia detection based on morphological information.
    Leuk Lymphoma. 2025 Dec 4:1-27. doi: 10.1080/10428194.2025.2583449.
    >> Share

  111. ANGELUCCI E, Deconinck E, Benoit TM, Braitsch K, et al
    Real-world study of tagraxofusp monotherapy in relapsed or refractory blastic plasmacytoid dendritic cell neoplasm.
    Leuk Lymphoma. 2025;66:2489-2497.
    >> Share

  112. HAAKSMA LH, Cloos J, Leeuw DC
    Flow cytometric and molecular MRD in AML: current methods, clinical applications and challenges.
    Leuk Lymphoma. 2025;66:2357-2368.
    >> Share

  113. ZHANG L, Yi M, Chen X, Guo Y, et al
    Measurable residual disease dynamics holding prognostic significance in pediatric patients with RUNX1::RUNX1T1-positive AML: results from AML-CAMS serial trials.
    Leuk Lymphoma. 2025;66:2457-2465.
    >> Share

  114. URRUTIA S, Jen WY, Sasaki K, Wiernik PH, et al
    Mortality and relapse dynamics in AML after three years of complete remission.
    Leuk Lymphoma. 2025;66:2498-2503.
    >> Share

  115. JERAJ R, Duan F, Mattison RJ, Romanoff J, et al
    Early assessment of treatment response in AML using FLT PET/cT: a trial of the ECOG-ACRIN Cancer Research Group (EAI141).
    Leuk Lymphoma. 2025;66:2765-2773.
    >> Share

  116. LANE AA, Papayannidis C, Angelucci E, McCloskey J, et al
    Optimizing capillary leak syndrome prevention and management in patients receiving tagraxofusp for blastic plasmacytoid dendritic cell neoplasm.
    Leuk Lymphoma. 2025;66:2569-2577.
    >> Share

  117. MARTIN C, Hill K, Isoardi K
    Application of the QT nomogram to ECG monitoring of QT prolongation in arsenic trioxide for acute promyelocytic myeloid leukaemia.
    Leuk Lymphoma. 2025;66:2728-2732.
    >> Share

  118. SUTTON E, Shanmuganathan N, Ross D
    Clinical and biological predictors of treatment-free remission in CML.
    Leuk Lymphoma. 2025;66:2578-2587.
    >> Share

  119. KENNEDY VE, Touya M, Spalding J, Young C, et al
    Real-world treatment adherence and persistence of FLT3 inhibitors as post-alloHCT maintenance therapy in patients with AML in the United States: a cohort study using administrative claims data.
    Leuk Lymphoma. 2025;66:2697-2707.
    >> Share

    November 2025
  120. GANJU N, Sharma M, Dhawan R, Oberoi G, et al
    Effect of tyrosine kinase inhibitors on sperm parameter and pituitary gonadal axis in males with chronic myeloid leukemia: a prospective cohort study.
    Leuk Lymphoma. 2025 Nov 20:1-8. doi: 10.1080/10428194.2025.2584688.
    >> Share

  121. MOHAMMED SALEH MF, Nasiri A, Kotb A, Ahmed SO, et al
    The emerging role of immunotherapy in improving outcomes in Down syndrome - associated acute lymphoblastic leukemia: an insightful review.
    Leuk Lymphoma. 2025 Nov 20:1-8. doi: 10.1080/10428194.2025.2590596.
    >> Share

  122. LAGANA A, Scalzulli E, Carmosino I, Bisegna ML, et al
    Early predictive factors of molecular relapse in chronic phase-chronic myeloid leukemia (CP-CML) patients after tyrosine kinase inhibitor (TKI) discontinuation.
    Leuk Lymphoma. 2025 Nov 20:1-5. doi: 10.1080/10428194.2025.2591778.
    >> Share

  123. SUN Y, Aviv H
    Neuroendocrine transdifferentiation of aggressive B-cell leukemia/lymphoma post CAR-T therapy.
    Leuk Lymphoma. 2025 Nov 19:1-4. doi: 10.1080/10428194.2025.2589375.
    >> Share

  124. CALVILLO CD, Cardenas Castro V, Shim KG, Arribas M, et al
    NGS-based monitoring of secondary acute lymphoblastic leukemia dynamics following lenalidomide maintenance in multiple myeloma patients.
    Leuk Lymphoma. 2025 Nov 19:1-7. doi: 10.1080/10428194.2025.2586084.
    >> Share

  125. CHO C, Redd R, Haydu JE, Johnson PC, et al
    Central nervous system involvement in chronic lymphocytic leukemia: a real-world analysis.
    Leuk Lymphoma. 2025 Nov 18:1-5. doi: 10.1080/10428194.2025.2581717.
    >> Share

  126. LATAGLIATA R, Carmosino I, Di Veroli A, Scalzulli E, et al
    Hemoglobin changes during long-lasting frontline treatment with Tyrosine-Kinase inhibitors in patients with chronic myeloid leukemia.
    Leuk Lymphoma. 2025 Nov 17:1-6. doi: 10.1080/10428194.2025.2586816.
    >> Share

  127. GUO X, Wang X, Wang Y, Rong L, et al
    Long-term remission of CBFA2T3::GLIS2-positive pediatric acute myeloid leukemia with myeloid sarcoma following unrelated cord blood transplantation.
    Leuk Lymphoma. 2025 Nov 13:1-4. doi: 10.1080/10428194.2025.2584684.
    >> Share

  128. CHEVILLON F, Dhedin N, Boissel N
    Allogeneic hematopoietic stem cell transplantation in adult with acute lymphoblastic leukemia: evolving indications and modalities in shifting landscape.
    Leuk Lymphoma. 2025 Nov 13:1-13. doi: 10.1080/10428194.2025.2584685.
    >> Share

  129. VALDOVINOS-ELIZALDE LE, Rios-Olais FA, Hernandez-Felix JH, Vasquez-Ortiz ZY, et al
    Prognostic value of HFA-ICOS risk assessment for cancer therapy-related cardiovascular toxicity in adults with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2025 Nov 11:1-9. doi: 10.1080/10428194.2025.2583445.
    >> Share

  130. SALTER B, Ge S, Garcia-Horton A, Berg T, et al
    Real-world experience and outcomes of decitabine/cedazuridine or azacitidine for the treatment of myelodysplastic syndrome/chronic myelomonocytic leukemia.
    Leuk Lymphoma. 2025 Nov 5:1-8. doi: 10.1080/10428194.2025.2577861.
    >> Share

  131. NGO D, Kaleka G, Yang D, Mokhtari S, et al
    Real world outcomes of patients with secondary acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation after induction with liposomal daunorubicin-cytarabine (CPX-351).
    Leuk Lymphoma. 2025 Nov 5:1-4. doi: 10.1080/10428194.2025.2584682.
    >> Share

  132. GOUZU Y, Ide Y, Shigeto S, Saito T, et al
    Chemotherapy-associated lineage shift of T/myeloid mixed-phenotype acute leukemia into AML-MRC: a case report.
    Leuk Lymphoma. 2025 Nov 5:1-5. doi: 10.1080/10428194.2025.2582716.
    >> Share

    October 2025
  133. ICHIMURA H, Kato S, Monna-Oiwa M, Andoh S, et al
    Comparative analysis of the acute myeloid leukemia-composite model and treatment-related mortality score in single-unit cord blood transplantation.
    Leuk Lymphoma. 2025 Oct 31:1-4. doi: 10.1080/10428194.2025.2571201.
    >> Share

  134. NING Y, Stinnett V, Middlezong W, Liang S, et al
    Detection of cytogenetic abnormalities using optical genome mapping in T-cell lymphoid leukemia with low mitotic index.
    Leuk Lymphoma. 2025 Oct 31:1-4. doi: 10.1080/10428194.2025.2562960.
    >> Share

  135. AZEVEDO RS, Braish J, Gener-Ricos G, Tang G, et al
    Cladribine, high-dose cytarabine, plus gemtuzumab ozogamicin (CLAG-GO) as frontline intensive therapy for fit patients with core-binding factor acute myeloid leukemia.
    Leuk Lymphoma. 2025 Oct 31:1-5. doi: 10.1080/10428194.2025.2568745.
    >> Share

  136. ZHAO Y, Chen J, Xu L, Lin D, et al
    Acute promyelocytic leukemia with TTMV::RARA fusion: a case report and mini review.
    Leuk Lymphoma. 2025 Oct 31:1-5. doi: 10.1080/10428194.2025.2571420.
    >> Share

  137. HUNTER CJ, Cheng W, Bewersdorf JP, Boddu P, et al
    Feasibility, safety and outcomes of patients with newly diagnosed acute myeloid leukemia discharged 'early' after intensive induction.
    Leuk Lymphoma. 2025 Oct 29:1-12. doi: 10.1080/10428194.2025.2578420.
    >> Share

  138. BAK A, Pasinska M, Jaskowiec A, Potoczek S, et al
    Germline predisposition to acute myeloid leukemia in polish patients.
    Leuk Lymphoma. 2025 Oct 27:1-8. doi: 10.1080/10428194.2025.2571421.
    >> Share

  139. STANGANELLI C, Cardoso F, Cabrera J, Damiani G, et al
    IGLV3-21 subset #2 without IGLV3-21(R110) in chronic lymphocytic leukemia, is it possible?
    Leuk Lymphoma. 2025 Oct 26:1-4. doi: 10.1080/10428194.2025.2561115.
    >> Share

  140. ARANI N, Rausch CR, Geppner A, Borthakur G, et al
    Cladribine and venetoclax combined with alemtuzumab in patients with relapsed/refractory T-cell prolymphocytic leukemia.
    Leuk Lymphoma. 2025 Oct 22:1-5. doi: 10.1080/10428194.2025.2566318.
    >> Share

  141. LIN J, He C, Cai Z, Chen J, et al
    Pediatric-inspired regimen abrogates the poor prognosis of adult early T-cell precursor acute lymphoblastic leukemia.
    Leuk Lymphoma. 2025 Oct 16:1-8. doi: 10.1080/10428194.2025.2558921.
    >> Share

  142. MCCORMICK B, Findley A, Diebold K, Bourne G, et al
    Clinical outcomes of allogeneic cell transplantation for patients with chronic myeloid leukemia.
    Leuk Lymphoma. 2025 Oct 10:1-11. doi: 10.1080/10428194.2025.2564766.
    >> Share

  143. PARK H, Lee JH, Lee JH, Park HS, et al
    Optimal conditioning intensity: favorable outcome of a 3-day busulfan based regimen in younger acute myeloid leukemia patients.
    Leuk Lymphoma. 2025 Oct 10:1-14. doi: 10.1080/10428194.2025.2560086.
    >> Share

  144. TADMOR T, Demeter J, Fagarasanu A, Kreitman RJ, et al
    Expert consensus opinion on the management of hairy cell leukemia in elderly patients.
    Leuk Lymphoma. 2025 Oct 10:1-7. doi: 10.1080/10428194.2025.2562961.
    >> Share

  145. WATRIN T, Seifert M, Dietrich S
    The tumor microenvironment in hairy cell leukemia (HCL) and splenic B cell lymphoma with prominent nucleoli (SBLPN).
    Leuk Lymphoma. 2025 Oct 6:1-10. doi: 10.1080/10428194.2025.2562951.
    >> Share

  146. HUANG YH, Liu FT, Wan CL, Wang ZJ, et al
    Venetoclax plus hypomethylating agents versus priming regimen as the first-line therapy for newly diagnosed acute myeloid leukemia with myelodysplasia-related changes: a propensity score-matched analysis.
    Leuk Lymphoma. 2025 Oct 6:1-11. doi: 10.1080/10428194.2025.2566317.
    >> Share

    September 2025
  147. WANG Y, Xiao X, Zheng H, Bai J, et al
    The discussion on the differences in immune microenvironment between low-risk and high-risk myelodysplastic syndromes and acute myeloid leukemia.
    Leuk Lymphoma. 2025 Sep 9:1-16. doi: 10.1080/10428194.2025.2549519.
    >> Share

  148. PARISI X, Ghosh A, Tang G, Jorgensen JL, et al
    Lineage switch of B-lymphoblastic leukemia with KMT2A::AFF1 fusion into acute myelomonocytic leukemia under blinatumomab therapy.
    Leuk Lymphoma. 2025 Sep 8:1-4. doi: 10.1080/10428194.2025.2549515.
    >> Share

  149. SINGH L, Rastogi K, Singh A, Sathapathy S, et al
    Methods for the analysis of leukemic infiltration within cerebrospinal fluid in acute lymphoblastic leukemia-a systematic review.
    Leuk Lymphoma. 2025 Sep 5:1-13. doi: 10.1080/10428194.2025.2550580.
    >> Share

  150. XU K, Mellios Z, Hyun J, Childerhouse A, et al
    Diagnosis and management of acute erythroid leukemia (AEL).
    Leuk Lymphoma. 2025 Sep 2:1-5. doi: 10.1080/10428194.2025.2553166.
    >> Share

  151. BRAZEL D, Hermel DJ, Saven A
    Threading through the data for chemotherapy-free alternatives in the treatment of hairy cell leukemia.
    Leuk Lymphoma. 2025 Sep 1:1-8. doi: 10.1080/10428194.2025.2548373.
    >> Share

  152. ABBASI-SHAHKOUH A, Rashidan K, Azadmehr A, Atashi A, et al
    Exploring the role of neutrophil extracellular traps in leukemia: a comprehensive review.
    Leuk Lymphoma. 2025 Sep 1:1-11. doi: 10.1080/10428194.2025.2547990.
    >> Share

    August 2025
  153. TESSIER S, Greipp PT, Jevremovic D, Alkhateeb HB, et al
    Acute leukemia of ambiguous lineage with KMT2A-alterations in adults.
    Leuk Lymphoma. 2025 Aug 25:1-6. doi: 10.1080/10428194.2025.2547988.
    >> Share

  154. LIPTON JH
    Indolent chronic myeloid leukemia - a historical dinosaur?
    Leuk Lymphoma. 2025 Aug 22:1-2. doi: 10.1080/10428194.2025.2536121.
    >> Share

  155. AMIRI D, Mirzaei M, Bahri T, Barkhordar M, et al
    Outcome of allogeneic hematopoietic cell transplantation in adult acute lymphoblastic leukemia patients who underwent myeloablative TBI-free conditioning regimen.
    Leuk Lymphoma. 2025 Aug 20:1-9. doi: 10.1080/10428194.2025.2548968.
    >> Share

  156. KARRAR O, Kantarjian H, Haddad FG, Azevedo RS, et al
    Outcomes and patterns of relapse with ponatinib-based therapy in patients with chronic myeloid leukemia in myeloid blast phase.
    Leuk Lymphoma. 2025 Aug 9:1-8. doi: 10.1080/10428194.2025.2542946.
    >> Share

  157. MATSUI S, Nakahara W, Fukuda S, Hosoya M, et al
    Intrathecal methotrexate for meningeal acute lymphoblastic leukemia in a hemodialysis patient.
    Leuk Lymphoma. 2025 Aug 9:1-4. doi: 10.1080/10428194.2025.2544067.
    >> Share

  158. PARK H, Lee JH, Lee JH, Park HS, et al
    Effectiveness of prophylactic intrathecal chemotherapy and risk factors of central nervous system relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia.
    Leuk Lymphoma. 2025 Aug 7:1-11. doi: 10.1080/10428194.2025.2541302.
    >> Share

  159. AGRAWAL V, Aldoss I, Pullarkat V
    Extramedullary sites of disease in B-cell acute lymphoblastic leukemia: incidence, biology, and treatment.
    Leuk Lymphoma. 2025 Aug 5:1-12. doi: 10.1080/10428194.2025.2541024.
    >> Share

  160. ZIELONKA K, Izdebski B, Drozd-Sokolowska J, Pruszczyk-Matusiak K, et al
    Venetoclax and obinutuzumab in first-line treatment of unfit patients with CLL - real-life data analysis of the Polish Adult leukemia group.
    Leuk Lymphoma. 2025 Aug 1:1-9. doi: 10.1080/10428194.2025.2535693.
    >> Share

    July 2025
  161. LU L, Liang J, Wang L, Chen Z, et al
    Venetoclax promotes acute myeloid leukemia cells apoptosis by decreasing ac4C modification and mRNA expression of IMP3 through downregulating NAT10.
    Leuk Lymphoma. 2025 Jul 31:1-11. doi: 10.1080/10428194.2025.2540445.
    >> Share

  162. PODGORICA M, Drivet E, Vestbostad J, Kvam AK, et al
    Azaindole 1, a selective Rock1/2 kinase inhibitor, induces G2/M arrest and cell death in B-cell acute lymphoblastic leukemia (B-ALL).
    Leuk Lymphoma. 2025 Jul 29:1-5. doi: 10.1080/10428194.2025.2536125.
    >> Share

  163. MULLIGAN SP, Thompson PA, Wight J, Anderson MA, et al
    Real-world utilization of Bruton tyrosine kinase inhibitors in relapsed/refractory chronic lymphocytic leukemia in Australia.
    Leuk Lymphoma. 2025 Jul 27:1-11. doi: 10.1080/10428194.2025.2533498.
    >> Share

  164. LIU YC, van Besien KW
    Chronic myelomonocytic leukemia (CMML): a genetically heterogeneous entity.
    Leuk Lymphoma. 2025 Jul 22:1-3. doi: 10.1080/10428194.2025.2527389.
    >> Share

  165. WU Y, Ke Q, Liu B, Luo W, et al
    KLF2 double variants (C274Y and H210N) in a splenic B-cell lymphoma/leukemia: diagnostic insights into splenic marginal zone lymphoma and mechanistic implications.
    Leuk Lymphoma. 2025 Jul 15:1-5. doi: 10.1080/10428194.2025.2532680.
    >> Share

  166. LI THS, Yuen CT, Hou HW, Lam CP, et al
    Expanding the phenotypic spectrum of DDX41-related myeloid neoplasms: a case of mature plasmacytoid dendritic cell proliferation associated with acute myeloid leukemia with germline DDX41 mutation.
    Leuk Lymphoma. 2025 Jul 14:1-3. doi: 10.1080/10428194.2025.2529451.
    >> Share

  167. ASHFAQ MO, Iqbal MS, Ashfaq L, Irfan U, et al
    Challenging diagnosis of chronic myelomonocytic leukemia (CMML) in a patient with Takayasu arteritis: case report.
    Leuk Lymphoma. 2025 Jul 13:1-4. doi: 10.1080/10428194.2025.2526792.
    >> Share

  168. KOFFMAN B, Warwick L, Haggert P, Patten PEM, et al
    A charter for improving care for people living with chronic lymphocytic leukemia: six principles for excellence.
    Leuk Lymphoma. 2025 Jul 12:1-7. doi: 10.1080/10428194.2025.2521656.
    >> Share

  169. UYANIK MS, Jabbour E, Short N, Sasaki K, et al
    Nelarabine-related rhabdomyolysis in adult patients with T-cell lymphoblastic leukemia/lymphoma: a report of 6 patients.
    Leuk Lymphoma. 2025 Jul 6:1-3. doi: 10.1080/10428194.2025.2521649.
    >> Share

  170. FENG J, Qian W, Shan S, Wang G, et al
    Azathioprine as a substitute for 6-mercaptopurine in childhood acute lymphoblastic leukemia: a single-center retrospective study.
    Leuk Lymphoma. 2025 Jul 6:1-9. doi: 10.1080/10428194.2025.2526795.
    >> Share

  171. GULLAKSEN SE, Omsland M, Brevik M, Letzner J, et al
    CML stem cells and their interactions and adaptations to tyrosine kinase inhibitors.
    Leuk Lymphoma. 2025;66:1211-1220.
    >> Share

    June 2025
  172. SLATER VE, Carnahan RM, Strouse CS, O'Rorke MA, et al
    Changes in first-line treatment patterns according to frailty in chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Leuk Lymphoma. 2025 Jun 26:1-12. doi: 10.1080/10428194.2025.2522373.
    >> Share

  173. SARANGARAJAN S, Meena JP, Gupta AK, Batra A, et al
    The prognostic implications of CDKN2A/2B deletion in childhood acute lymphoblastic leukemia: a systematic review and meta-analysis.
    Leuk Lymphoma. 2025 Jun 25:1-14. doi: 10.1080/10428194.2025.2521658.
    >> Share

  174. MAURO MJ, Hehlmann R, Williams LA, Goldberg SL, et al
    Five-year molecular response and overall survival with first- and second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase: a prospective, observational study - SIMPLICITY.
    Leuk Lymphoma. 2025 Jun 22:1-10. doi: 10.1080/10428194.2025.2495369.
    >> Share

  175. SWAIN RN, Pattanaik S, Jain A, Wadhera S, et al
    Comparable response rates of venetoclax 50 mg with posaconazole versus venetoclax 400 mg despite lower pharmacokinetic exposure in newly diagnosed acute myeloid leukemia: less is enough.
    Leuk Lymphoma. 2025 Jun 22:1-5. doi: 10.1080/10428194.2025.2519921.
    >> Share

  176. KUNDU R, Soni K, Kundu R, Mukherjee S, et al
    State-wise disparities and temporal trends in acute myeloid leukemia (AML) in the United States of America (USA).
    Leuk Lymphoma. 2025 Jun 20:1-6. doi: 10.1080/10428194.2025.2515598.
    >> Share

  177. PUROHIT BN, Mohan V, Capoor V, Jain S, et al
    Lower-dose venetoclax (LoVe) based regimes in children with acute leukemia.
    Leuk Lymphoma. 2025 Jun 18:1-4. doi: 10.1080/10428194.2025.2519920.
    >> Share

  178. LAI CE, Leahy TP, Turner AJ, Thomassen A, et al
    Effectiveness of olutasidenib versus ivosidenib in patients with mutated isocitrate dehydrogenase 1 acute myeloid leukemia who are relapsed or refractory to venetoclax: the 2102-HEM-101 trial versus a US electronic health record-based external control
    Leuk Lymphoma. 2025 Jun 13:1-12. doi: 10.1080/10428194.2025.2514894.
    >> Share

  179. SMITH CIE
    Resistance to BTK inhibitors in leukemia: cysteine 481 in BTK equals cysteine 515 in the BTK isomer BTK-C.
    Leuk Lymphoma. 2025 Jun 12:1-2. doi: 10.1080/10428194.2025.2518433.
    >> Share

  180. DAMPMANN M, von Tresckow B, Reinhardt HC, Kuppers R, et al
    Insights into the pathogenesis and biology of chronic lymphocytic leukemia through analysis of its B-cell receptor.
    Leuk Lymphoma. 2025 Jun 10:1-10. doi: 10.1080/10428194.2025.2513005.
    >> Share

  181. KAMALLOO H, Fathi M, Bavandi S, Asadi F, et al
    Recent advances in monoclonal antibody development for treatment of B-cell acute lymphoblastic leukemia.
    Leuk Lymphoma. 2025 Jun 2:1-13. doi: 10.1080/10428194.2025.2507198.
    >> Share

  182. JANY J, Mikesch JH, Wethmar K, Baden D, et al
    Prognostic impact of WBC kinetics after induction therapy in patients with acute myeloid leukemia (AML).
    Leuk Lymphoma. 2025 Jun 2:1-12. doi: 10.1080/10428194.2025.2512029.
    >> Share

    May 2025
  183. LEVY V, Srivastava T, Gautam R, Swami S, et al
    Toxicity, progression-free survival, and quality of life of patients treated with zanubrutinib versus ibrutinib: a Q-TWiST analysis from the ALPINE study in relapsed or refractory chronic lymphocytic leukemia.
    Leuk Lymphoma. 2025 May 23:1-9. doi: 10.1080/10428194.2025.2506501.
    >> Share

  184. MEHTA P, Ngo D, Tinajero J, Agrawal V, et al
    Comparison of CALGB 10403 and HyperCVAD in the treatment of Philadelphia chromosome negative acute lymphoblastic leukemia in adults >/=40 years old.
    Leuk Lymphoma. 2025 May 21:1-5. doi: 10.1080/10428194.2025.2506003.
    >> Share

  185. SHI C, Li Y, Zou X, Yao D, et al
    AP2M1 is a prognostic marker associated with cell cycle arrest and the tumor immune microenvironment in acute myeloid leukemia.
    Leuk Lymphoma. 2025 May 19:1-15. doi: 10.1080/10428194.2025.2504161.
    >> Share

  186. HILL JW, Marvin-Peek J, Sasaki K, Bresser S, et al
    Central nervous system relapse of core-binding factor acute myeloid leukemia.
    Leuk Lymphoma. 2025 May 19:1-4. doi: 10.1080/10428194.2025.2506505.
    >> Share

  187. TADMOR T, Lavie G, Melamed G, Alapi H, et al
    Intake of benzodiazepines in treatment naive chronic lymphocytic leukemia patients is associate with a shorter time to first treatment.
    Leuk Lymphoma. 2025 May 15:1-6. doi: 10.1080/10428194.2025.2504155.
    >> Share

  188. OTHMAN T, Lo MM, Andreadis CB, Damon LE, et al
    Single-center experience with nelarabine, etoposide, and cyclophosphamide in adults with relapsed/refractory T-acute lymphoblastic leukemia/lymphoma.
    Leuk Lymphoma. 2025 May 7:1-4. doi: 10.1080/10428194.2025.2496333.
    >> Share

  189. GORDON BK, Woyach JA
    The challenge of targeting key drivers of CLL and sequencing therapy in an era of experimental therapeutics.
    Leuk Lymphoma. 2025;66:838-846.
    >> Share

  190. MCKEAGUE S, Tam C
    Prognostic factors in chronic lymphocytic leukaemia - the old, the new and the future.
    Leuk Lymphoma. 2025;66:847-857.
    >> Share

  191. RAMACHANDRA N, Vegivinti CTR, Sahu S, Sanawar R, et al
    Transforming growth factor beta receptor type I (TGF-betaRI) kinase inhibitors IOA-359 and IOA-360 stimulate erythropoiesis in MDS.
    Leuk Lymphoma. 2025;66:920-929.
    >> Share

    April 2025
  192. SHALLIS RM, Weiss JJ, Winer ES, Badar T, et al
    Feasibility and safety of outpatient hypomethylating agent and venetoclax initiation with and without ramp-up for newly diagnosed acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).
    Leuk Lymphoma. 2025 Apr 28:1-5. doi: 10.1080/10428194.2025.2496339.
    >> Share

  193. LAGANA A, Kasmi D, Diverio D, Bisegna ML, et al
    CD99 expression in acute myeloid leukemia with FLT3 internal tandem duplications (FLT3-ITD(mut)-AML): a flow-cytometric marker for an accurate diagnostic workup.
    Leuk Lymphoma. 2025 Apr 28:1-6. doi: 10.1080/10428194.2025.2497392.
    >> Share

  194. ELHODAKY M, Duckett D, Santana-Santos L, Oh TS, et al
    Clinicopathological and global methylation profiling of acute myeloid leukemia with mutations in NPM1 and clonal hematopoiesis-related genes.
    Leuk Lymphoma. 2025 Apr 25:1-8. doi: 10.1080/10428194.2025.2495105.
    >> Share

  195. BEHMAN J, Longobardi S, Kang G, Lingamurthy M, et al
    CD5- B-cell lymphocytic leukemia -a diagnostic exclusion of splenic B-cell leukemia with prominent nuclei challenging current international consensus.
    Leuk Lymphoma. 2025 Apr 22:1-4. doi: 10.1080/10428194.2025.2492608.
    >> Share

  196. LEVANON E, Peles I, Meyer E, Tarab E, et al
    Prognostic impact of fever at presentation in acute myeloid leukemia: a retrospective cohort study.
    Leuk Lymphoma. 2025 Apr 17:1-11. doi: 10.1080/10428194.2025.2493342.
    >> Share

  197. PATEL M, Zabor EC, Mohamed A, Zureigat H, et al
    Impact of TP53 mutation on survival outcomes in acute lymphoblastic leukemia at a tertiary center.
    Leuk Lymphoma. 2025 Apr 9:1-6. doi: 10.1080/10428194.2025.2482131.
    >> Share

  198. DHAKAL P, Armitage JO, Bhatt VR
    Academic and community cancer center collaboration in acute myeloid leukemia: a road map to optimize care delivery.
    Leuk Lymphoma. 2025 Apr 1:1-11. doi: 10.1080/10428194.2025.2484640.
    >> Share

    March 2025
  199. KUGLER E, Dasdemir E, Bataller A, Wang B, et al
    Mutation dynamics from diagnosis to relapse in acute myeloid leukemia with chromosomal 7 deletions.
    Leuk Lymphoma. 2025 Mar 31:1-13. doi: 10.1080/10428194.2025.2477723.
    >> Share

  200. JOHANSSON ALM S, Orrsjo G, Shah Barkhordar G, Rehammar A, et al
    Prognostic significance of deep sequencing for analysis of measurable residual disease in acute myeloid leukemia with NPM1 mutation.
    Leuk Lymphoma. 2025 Mar 31:1-11. doi: 10.1080/10428194.2025.2482130.
    >> Share

  201. FERREIRA JE, Wang CP, Aguayo-Hiraldo P, Raca G, et al
    Achievement of durable remission of relapsed/refractory acute myeloid leukemia in a child using venetoclax monotherapy.
    Leuk Lymphoma. 2025 Mar 25:1-5. doi: 10.1080/10428194.2025.2482135.
    >> Share

  202. ROBAK T, Pluta A, Robak P, Janus A, et al
    Burkitt lymphoma in patients with chronic lymphocytic leukemia and other indolent B-cell lymphoid malignancies.
    Leuk Lymphoma. 2025 Mar 25:1-13. doi: 10.1080/10428194.2025.2475337.
    >> Share

  203. JAIN N, Eyre TA, Winfree KB, Bhandari NR, et al
    Real-world outcomes after discontinuation of covalent BTK inhibitor-based therapy in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Leuk Lymphoma. 2025 Mar 23:1-13. doi: 10.1080/10428194.2025.2482132.
    >> Share

  204. MONSEES EL, Hauch RT, Wrzeszcz A, Spohn M, et al
    A case report of a pediatric T-cell acute lymphoblastic leukemia with a subclonal GCC2::PDGFRB t(2;5) translocation - implementation for the selection of MRD-targets.
    Leuk Lymphoma. 2025 Mar 19:1-5. doi: 10.1080/10428194.2025.2480395.
    >> Share

  205. AMREIN PC, Preffer FI, Fell G, Attar EC, et al
    Ixazomib in addition to chemotherapy for the treatment of acute myeloid leukemia in older adults.
    Leuk Lymphoma. 2025 Mar 12:1-11. doi: 10.1080/10428194.2025.2476655.
    >> Share

  206. HOECHSTETTER MA, Wendtner CM
    Clinical trials in early-stage CLL: what has been learned and what's next?
    Leuk Lymphoma. 2025;66:378-388.
    >> Share

  207. ALHAJAHJEH A, Patel KK, Shallis RM, Podoltsev NA, et al
    Cost-effectiveness of Enasidenib versus conventional care for older patients with IDH2-mutant refractory/relapsed AML.
    Leuk Lymphoma. 2025;66:488-496.
    >> Share

  208. LI Q, Xing S, Zhang H, Mao X, et al
    FISH combined with RT-PCR facilitates classification of Chinese adult patients with B-other ALL through improved identification of ZNF384 rearrangement.
    Leuk Lymphoma. 2025;66:507-515.
    >> Share

    February 2025
  209. TAN M, Lasica M, Donati V, Rady K, et al
    Avascular necrosis in older adolescents and adults with acute lymphoblastic leukemia treated with FRALLE protocols: a multicenter analysis of incidence, risk factors and morbidity.
    Leuk Lymphoma. 2025 Feb 27:1-7. doi: 10.1080/10428194.2025.2470784.
    >> Share

  210. GRUESSNER C, Wiestner A, Sun C
    Resistance mechanisms and approach to chronic lymphocytic leukemia after BTK inhibitor therapy.
    Leuk Lymphoma. 2025 Feb 19:1-13. doi: 10.1080/10428194.2025.2466101.
    >> Share

  211. SHESTAKOVA A, Haghighi N, Zhang Y, Tarabay J, et al
    Mutational landscape of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) involving the central nervous system.
    Leuk Lymphoma. 2025 Feb 18:1-6. doi: 10.1080/10428194.2025.2452341.
    >> Share

  212. SUN Y, Liu N, Liu Y, Deng J, et al
    Isolated CNS B lymphoid/myeloid bilineage relapse following allogeneic hematopoietic stem cell transplantation in adult acute myeloid leukemia with KMT2A::MLLT1 rearrangement.
    Leuk Lymphoma. 2025 Feb 10:1-4. doi: 10.1080/10428194.2025.2460046.
    >> Share

  213. THOMAS CJ, Porter D, Van Deerlin VM, Bhattacharyya S, et al
    Aleukemic soft-tissue relapse post allogeneic hematopoietic cell transplantation in T-prolymphocytic leukemia.
    Leuk Lymphoma. 2025 Feb 8:1-4. doi: 10.1080/10428194.2025.2462950.
    >> Share

  214. LANG F, Voss A, Kobbe G, Junghanss C, et al
    Final analysis of the GMALL-PH-01 trial: phase II study of standard chemotherapy in combination with dasatinib in first line treatment of Philadelphia chromosome positive acute lymphoblastic leukemia.
    Leuk Lymphoma. 2025 Feb 8:1-9. doi: 10.1080/10428194.2025.2460737.
    >> Share

  215. CHIN KK, Derkach A, Famulare C, Gupta GK, et al
    HMA/VEN treatment modifications and associated outcomes in IDH-mutant AML.
    Leuk Lymphoma. 2025;66:270-278.
    >> Share

    January 2025
  216. KRSTEVSKA BOZHINOVIKJ E, Matevska-Geshkovska N, Staninova Stojovska M, Gjorgievska E, et al
    Presence of minimal residual disease determined by next-generation sequencing is not a reliable prognostic biomarker in children with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2025 Jan 22:1-8. doi: 10.1080/10428194.2025.2456100.
    >> Share

  217. JEONG Y
    Comprehensive analysis of clinical, pathological, and molecular features in chronic myelomonocytic leukemia: frequent ASXL1 and NRAS mutations and higher mutation burden in myeloproliferative CMML compared to myelodysplastic CMML.
    Leuk Lymphoma. 2025 Jan 17:1-10. doi: 10.1080/10428194.2025.2453093.
    >> Share

  218. TESSIER S, McCullough KB, Gangat N, Begna KH, et al
    Venetoclax in combination with fludarabine, cytarabine, granulocyte colony stimulating factor, and idarubicin (FLAG-Ida) in patients with acute leukemia of ambiguous lineage and acute lymphoblastic leukemia.
    Leuk Lymphoma. 2025 Jan 16:1-5. doi: 10.1080/10428194.2024.2443017.
    >> Share

  219. HEILBRONNER AK, Blumberg O, Krez A, McMahon DJ, et al
    High incidence of multi-joint osteonecrosis in first year following treatment for acute lymphoblastic leukemia.
    Leuk Lymphoma. 2025 Jan 15:1-4. doi: 10.1080/10428194.2025.2452340.
    >> Share

  220. ZHU H, Zhang C, Huang L, Zhang B, et al
    Identification of possible drug treatment targets and related immune cell infiltration properties in acute myeloid leukemia utilizing robust rank aggregation algorithm.
    Leuk Lymphoma. 2025 Jan 15:1-12. doi: 10.1080/10428194.2025.2451064.
    >> Share

  221. LI M, Zhao DQ, Kong XY, Wang SM, et al
    Effects of SCT genetic polymorphisms on methotrexate concentrations and toxicities in Chinese children with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2025 Jan 11:1-11. doi: 10.1080/10428194.2025.2451059.
    >> Share

  222. SENAPATI J, Kantarjian H, Habib D, Haddad FG, et al
    Frontline immunotherapeutic combination strategies in adult B-cell acute lymphoblastic leukemia: reducing chemotherapy intensity and toxicity and harnessing efficacy.
    Leuk Lymphoma. 2025 Jan 10:1-12. doi: 10.1080/10428194.2025.2449582.
    >> Share

  223. ZHANG F, Liu Y, Zhu Y, Wang Q, et al
    Molecular, clinical, and prognostic implications of RAS pathway alterations in adult acute myeloid leukemia.
    Leuk Lymphoma. 2025 Jan 2:1-11. doi: 10.1080/10428194.2024.2441855.
    >> Share

  224. YSEBAERT L, Mouchel PL, Laurent C, Quillet-Mary A, et al
    The multi-faceted roles of MYC in the prognosis of chronic lymphocytic leukemia.
    Leuk Lymphoma. 2025 Jan 2:1-13. doi: 10.1080/10428194.2024.2447362.
    >> Share

    December 2024
  225. AVGERINOU G, Solomou EE, Filippidou M, Perganti F, et al
    Chemotherapy-free approach with arsenic trioxide and all-trans retinoic acid in children with acute promyelocytic leukemia.
    Leuk Lymphoma. 2024 Dec 28:1-4. doi: 10.1080/10428194.2024.2445701.
    >> Share

  226. GUGLIELMANA V, Rossi D
    Prognostic and predictive impact of NOTCH1 mutation in chronic lymphocytic leukemia: a systematic review.
    Leuk Lymphoma. 2024 Dec 27:1-10. doi: 10.1080/10428194.2024.2441858.
    >> Share

  227. NILSSON MS, Martner A, Wennstrom L, Hansson M, et al
    Consistency of the efficacy of immunotherapy with histamine dihydrochloride and low-dose interleukin-2 for relapse prevention in acute myeloid leukemia.
    Leuk Lymphoma. 2024 Dec 24:1-3. doi: 10.1080/10428194.2024.2444466.
    >> Share

  228. DAMPMANN M, Kibler A, von Tresckow J, Reinhardt HC, et al
    Single-cell analysis of a bi-clonal chronic lymphocytic leukemia reveals two clones with distinct gene expression pattern.
    Leuk Lymphoma. 2024 Dec 17:1-9. doi: 10.1080/10428194.2024.2438804.
    >> Share

  229. OLIAI C, Park S, Damon LE, Jonas BA, et al
    CPX-351 plus gemtuzumab ozogamicin for relapsed/refractory acute myelogenous leukemia: a University of California Hematologic Malignancies Consortium trial.
    Leuk Lymphoma. 2024 Dec 17:1-7. doi: 10.1080/10428194.2024.2438809.
    >> Share

  230. SHELLEY CS, Galiegue-Zouitina S, Andritsos LA, Epperla N, et al
    The role of the JunD-RhoH axis in the pathogenesis of hairy cell leukemia and its ability to identify existing therapeutics that could be repurposed to treat relapsed or refractory disease.
    Leuk Lymphoma. 2024 Dec 17:1-19. doi: 10.1080/10428194.2024.2438800.
    >> Share

  231. ISHIKAWA C, Mori N
    ML385, a selective inhibitor of Nrf2, demonstrates efficacy in the treatment of adult T-cell leukemia.
    Leuk Lymphoma. 2024 Dec 17:1-12. doi: 10.1080/10428194.2024.2441875.
    >> Share

  232. KOVACH AE, Komova D, Itov A, Gaskova M, et al
    Pediatric therapy-related hematologic neoplasms show enrichment for KMT2A rearrangement and lymphoblastic phenotype.
    Leuk Lymphoma. 2024;65:1840-1852.
    >> Share

  233. MINA A
    Targeted therapy in acute T-cell leukemia/lymphoma: are we close?
    Leuk Lymphoma. 2024 Dec 1:1-3. doi: 10.1080/10428194.2024.2432575.
    >> Share

  234. PAISIOU A, OIkonomopoulou C, Pavlidis D, Ampatzidou M, et al
    CDKN2A/B deletion as an independent negative prognostic factor for allogeneic hematopoietic stem cell transplantation in childhood B cell precursor acute lymphoblastic leukemia.
    Leuk Lymphoma. 2024 Dec 1:1-4. doi: 10.1080/10428194.2024.2434177.
    >> Share

  235. RIOS-OLAIS FA, Rodriguez-Rodriguez S, Mora-Canas A, Ramos-Penafiel CO, et al
    Impact of the addition of rituximab in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Leuk Lymphoma. 2024 Dec 1:1-4. doi: 10.1080/10428194.2024.2432582.
    >> Share

  236. EHRMANN AS, Zadro A, Tausch E, Schneider C, et al
    The NOTCH1 and miR-34a signaling network is affected by TP53 alterations in CLL.
    Leuk Lymphoma. 2024;65:1941-1953.
    >> Share

  237. ARAD-COHEN N, Messinger Y, Barzilai-Birenboim S, Ben-Harosh M, et al
    National study reveals gram negative bacteremia on contemporary pediatric AML protocol.
    Leuk Lymphoma. 2024;65:1991-1999.
    >> Share

  238. TASHAKORI M, Yohe S, Linden MA, McKenna RW, et al
    The prognostic effect of blast count in TP53 mutant myeloid neoplasms -the Minnesota experience.
    Leuk Lymphoma. 2024;65:2151-2162.
    >> Share

  239. BOHN JP, Stolzlechner V, Gobel G, Pirklbauer M, et al
    Reduced prognostic value of beta-2-microglobulin for time to first treatment in CLL patients with compromised kidney function.
    Leuk Lymphoma. 2024;65:2108-2115.
    >> Share

    November 2024
  240. PAUL S, Jabbour E, Nichols ED, Short NJ, et al
    Blinatumomab for the treatment of acute lymphoblastic leukemia in a real-world setting: clinical vignettes.
    Leuk Lymphoma. 2024 Nov 29:1-11. doi: 10.1080/10428194.2024.2426052.
    >> Share

  241. SHORT NJ, Wierzbowska A, Cluzeau T, Laribi K, et al
    Azacitidine and venetoclax with or without pevonedistat in patients with newly diagnosed acute myeloid leukemia.
    Leuk Lymphoma. 2024 Nov 28:1-11. doi: 10.1080/10428194.2024.2431878.
    >> Share

  242. MIMS A, Xie Z, Potluri R, Rotter D, et al
    Oral azacitidine maintenance after intensive chemotherapy versus venetoclax and azacitidine: real world outcomes in newly diagnosed acute myeloid leukemia.
    Leuk Lymphoma. 2024 Nov 28:1-9. doi: 10.1080/10428194.2024.2425792.
    >> Share

  243. COSTA A, Scalzulli E, Carmosino I, Ielo C, et al
    Clinical and biological advances of critical complications in acute myeloid leukemia.
    Leuk Lymphoma. 2024 Nov 24:1-20. doi: 10.1080/10428194.2024.2425051.
    >> Share

  244. ARRIGO G, Scaldaferri M, Audisio E, Boscaro E, et al
    Arsenic trioxide neurotoxicity in acute promyelocytic leukemia patients: a single center experience.
    Leuk Lymphoma. 2024 Nov 8:1-2. doi: 10.1080/10428194.2024.2427266.
    >> Share

  245. KORSHOLM C, Bulow C, Christensen M, Dalhoff K, et al
    Drug exposure and measurable residual disease in chronic lymphocytic leukemia: a systematic review.
    Leuk Lymphoma. 2024 Nov 7:1-11. doi: 10.1080/10428194.2024.2412289.
    >> Share

  246. LECORNEC N, Duchmann M, Itzykson R
    Single-cell sequencing applications in acute myeloid leukemia.
    Leuk Lymphoma. 2024 Nov 4:1-15. doi: 10.1080/10428194.2024.2422833.
    >> Share

  247. TAM C, Zhao FL, Azam S, Li SC, et al
    Real-world treatment patterns and outcomes for patients with CLL using the Australian pharmaceutical benefits scheme (PBS) dataset.
    Leuk Lymphoma. 2024;65:1576-1585.
    >> Share

    October 2024
  248. THARAKAN S, Tremblay D, Azzi J
    Adoptive cell therapy in acute myeloid leukemia: the current landscape and emerging strategies.
    Leuk Lymphoma. 2024 Oct 25:1-14. doi: 10.1080/10428194.2024.2414112.
    >> Share

  249. ROTTER LK, Alhajahjeh A, Stempel JM, Grimshaw AA, et al
    Analyzing determinants of premature trial discontinuation in leukemia clinical trials.
    Leuk Lymphoma. 2024 Oct 23:1-9. doi: 10.1080/10428194.2024.2416565.
    >> Share

  250. KIM SA, Jung M, Kim H, Byun JM, et al
    MG4101, an allogeneic natural killer cell, in patients with relapsed or refractory acute myeloid leukemia: a pilot study.
    Leuk Lymphoma. 2024 Oct 22:1-8. doi: 10.1080/10428194.2024.2414903.
    >> Share

  251. DEHGHANI SS, Wang Y, Ramesh KH, Cooper D, et al
    Atypical chronic myeloid leukemia (CML) with ETV6-ABL1 mutation managed successfully with a third-generation TKI and hematopoietic stem cell transplant.
    Leuk Lymphoma. 2024 Oct 18:1-3. doi: 10.1080/10428194.2024.2403666.
    >> Share

  252. RIBERA JM, Torrent A
    Novel prognostic factors and therapeutic advances in adult acute lymphoblastic leukemia.
    Leuk Lymphoma. 2024 Oct 18:1-11. doi: 10.1080/10428194.2024.2416569.
    >> Share

  253. KANKARIA RA, Jones JB, Zargari M, Alexander DW, et al
    Complete remission in a case of acute undifferentiated leukemia with novel combination therapy of FLAG-IDA and venetoclax.
    Leuk Lymphoma. 2024 Oct 16:1-4. doi: 10.1080/10428194.2024.2416573.
    >> Share

  254. MOHAMMAD EM, El-Ayadi M, Kamel A, Ebeid E, et al
    Early impact of treatment modifications adopted for acute lymphoblastic leukemia during SARS-CoV-2 pandemic; a single center experience and lessons for LMICs.
    Leuk Lymphoma. 2024 Oct 9:1-7. doi: 10.1080/10428194.2024.2411432.
    >> Share

  255. SHANG Q, Wang Y, Lu A, Jia Y, et al
    Impact of pre-infusion disease burden on outcomes in pediatric relapsed/refractory B-cell lymphoblastic leukemia following anti-CD19 CAR T-cell therapy.
    Leuk Lymphoma. 2024 Oct 8:1-10. doi: 10.1080/10428194.2024.2406958.
    >> Share

  256. BRUNER SA, DiPippo AJ, Rausch CR
    Dose-adjusted direct oral anticoagulants (DOACs) in patients with acute leukemia: experience of a tertiary cancer care center.
    Leuk Lymphoma. 2024 Oct 7:1-3. doi: 10.1080/10428194.2024.2411626.
    >> Share

  257. SHADMAN M, Salkar M, Srivastava B, Karve S, et al
    Real-world outcomes following ibrutinib dose reduction in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Leuk Lymphoma. 2024 Oct 1:1-10. doi: 10.1080/10428194.2024.2402814.
    >> Share

    September 2024
  258. ZABLONSKI KG, Skupa SA, Eiken AP, Sundaram S, et al
    Targeted BET inhibition with OPN-51107 synergizes with venetoclax in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2024 Sep 27:1-9. doi: 10.1080/10428194.2024.2398663.
    >> Share

  259. SHANGGUAN X, Huang Y, Chen C, Wu W, et al
    Prognostic assessment value of immune escape-related genes in patients with acute myeloid leukemia.
    Leuk Lymphoma. 2024 Sep 23:1-12. doi: 10.1080/10428194.2024.2404957.
    >> Share

  260. KOPMAR NE, Qu X, Liu Y, Gooley TA, et al
    Prognostic significance of chromosomal genomic array testing in adults with newly-diagnosed acute lymphoblastic leukemia.
    Leuk Lymphoma. 2024 Sep 19:1-4. doi: 10.1080/10428194.2024.2404959.
    >> Share

  261. DE SA H, Deloughery T, Kaempf A, Lachowiez C, et al
    Thromboprophylaxis with intermediate dose enoxaparin during asparaginase containing induction for young adults with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2024 Sep 18:1-10. doi: 10.1080/10428194.2024.2405874.
    >> Share

  262. OMRAN MM, Ibrahim AB, Abdelfattah R, Moussa HS, et al
    The interplay of knowledge, motivation, and treatment response in medication adherence among patients with chronic myeloid leukemia treated with Imatinib.
    Leuk Lymphoma. 2024 Sep 18:1-8. doi: 10.1080/10428194.2024.2403671.
    >> Share

  263. CHEN EC, Flamand Y, Tiao E, DeAngelo DJ, et al
    Incidence, duration, and severity of neutropenia in adults with B-cell acute lymphoblastic leukemia receiving blinatumomab consolidation.
    Leuk Lymphoma. 2024 Sep 16:1-8. doi: 10.1080/10428194.2024.2402808.
    >> Share

  264. YIN Z, Gao Y, Bu X, Wang J, et al
    Homoharringtonine sensitized resistant acute myeloid leukemia cells to venetoclax-induced apoptosis.
    Leuk Lymphoma. 2024 Sep 5:1-13. doi: 10.1080/10428194.2024.2400228.
    >> Share

  265. HUNTER S, Ryland G, Pang JM, Ninkovic S, et al
    Chronic lymphocytic leukemia with MDM2 amplification as an alternative pathway to TP53 dysfunction.
    Leuk Lymphoma. 2024 Sep 4:1-4. doi: 10.1080/10428194.2024.2398659.
    >> Share

  266. GIL KB, Abbott D, Amaya ML, Schwartz M, et al
    Response to intensive induction chemotherapy after failure of frontline azacitidine and venetoclax in acute myeloid leukemia.
    Leuk Lymphoma. 2024 Sep 4:1-3. doi: 10.1080/10428194.2024.2397570.
    >> Share

  267. DEODATO M, Frustaci AM, Zappaterra A, Rapella A, et al
    Advances in the understanding of molecular genetics and therapy of Richter transformation in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2024 Sep 2:1-12. doi: 10.1080/10428194.2024.2398660.
    >> Share

  268. HAYASHI H, Morikawa Y, Akahoshi S, Ikegawa K, et al
    Octreotide as prophylaxis against asparaginase-associated pancreatitis: a case series study.
    Leuk Lymphoma. 2024;65:1366-1369.
    >> Share

  269. RAVANDI F, Subklewe M, Walter RB, Vachhani P, et al
    Safety and tolerability of AMG 330 in adults with relapsed/refractory AML: a phase 1a dose-escalation study.
    Leuk Lymphoma. 2024;65:1281-1291.
    >> Share

  270. ABUASAB T, Mohamed S, Pemmaraju N, Kadia TM, et al
    BRAF mutation in myeloid neoplasm: incidences and clinical outcomes.
    Leuk Lymphoma. 2024;65:1344-1349.
    >> Share

  271. SABILE JMG, Swords R, Tyner JW
    Evaluating targeted therapies in older patients with TP53-mutated AML.
    Leuk Lymphoma. 2024;65:1201-1218.
    >> Share

  272. KOBAYASHI Y, Ando K, Imaizumi Y, Sakamoto H, et al
    RUNX1 expression is regulated by a super-enhancer and is a therapeutic target in adult T-cell leukemia/lymphoma.
    Leuk Lymphoma. 2024 Sep 1:1-13. doi: 10.1080/10428194.2024.2393258.
    >> Share

    August 2024
  273. SCHWARTZ MS, Muffly LS
    Predicting relapse in acute lymphoblastic leukemia.
    Leuk Lymphoma. 2024 Aug 31:1-7. doi: 10.1080/10428194.2024.2387728.
    >> Share

  274. OSTERGAARD A, Boer JM, van Leeuwen FN, Pieters R, et al
    IKZF1 in acute lymphoblastic leukemia: the rise before the fall?
    Leuk Lymphoma. 2024 Aug 29:1-11. doi: 10.1080/10428194.2024.2396046.
    >> Share

  275. NGO D, Tinajero J, Song JY, Ma H, et al
    The characterization and the impact of CSF pleocytosis during blinatumomab therapy for adult acute lymphoblastic leukemia.
    Leuk Lymphoma. 2024 Aug 18:1-9. doi: 10.1080/10428194.2024.2392823.
    >> Share

  276. PRASERTSAN P, McNeil EB, Songthawee N, Chavananon S, et al
    Risk factors and development of a predictive score model for tumor lysis syndrome in childhood leukemia: a 10-year experience from a single tertiary hospital in Thailand.
    Leuk Lymphoma. 2024 Aug 18:1-7. doi: 10.1080/10428194.2024.2390582.
    >> Share

  277. JEANSELME P, Tavitian S, Lapierre L, Vergez F, et al
    Long-term exposure and response to azacitidine for post-hematopoietic stem cell transplantation relapse of early T-cell precursor acute lymphoblastic leukemia: a case report and review of the literature.
    Leuk Lymphoma. 2024 Aug 14:1-6. doi: 10.1080/10428194.2024.2390572.
    >> Share

  278. CELLINI A, Salvalaggio A, Velasco R, Arnan M, et al
    Arsenic trioxide-induced peripheral neuropathy: prospective clinical and neurophysiological evaluation in a cohort of patients with acute promyelocytic leukemia.
    Leuk Lymphoma. 2024 Aug 13:1-4. doi: 10.1080/10428194.2024.2391899.
    >> Share

  279. PELLAND AA, Deschenes-Simard X, Savard X, Giguere P, et al
    Outcomes of adults with refractory or relapsed acute myeloid leukemia treated with azacitidine and venetoclax compared to other therapies: a multicenter retrospective study.
    Leuk Lymphoma. 2024 Aug 11:1-9. doi: 10.1080/10428194.2024.2390574.
    >> Share

  280. HU D, Shen K, Guo Y, Bao XB, et al
    The clinical implications of BCOR mutations in a large cohort of acute myeloid leukemia patients: a 5-year single-center retrospective study.
    Leuk Lymphoma. 2024 Aug 10:1-10. doi: 10.1080/10428194.2024.2387730.
    >> Share

  281. LIN L, Xue S, Chen J, Gu C, et al
    Olaparib combined with low-dose chemotherapy for relapsed AML1::ETO positive acute myeloid leukemia in elderly patient.
    Leuk Lymphoma. 2024;65:1181-1185.
    >> Share

  282. VERVOORDELDONK MYL, Hengeveld PJ, Levin MD, Langerak AW, et al
    B cell receptor signaling proteins as biomarkers for progression of CLL requiring first-line therapy.
    Leuk Lymphoma. 2024;65:1031-1043.
    >> Share

  283. MAEKAWA F, Hayashida M, Takeoka K, Fukutsuka K, et al
    Two recurrent types of IGH::5' BCL2 breakpoints representing cytogenetic ins(14;18)(q32;q21q21) and t(14;18)(q32;q21), mediated by the VDJ and class switch recombination processes, respectively.
    Leuk Lymphoma. 2024;65:1100-1109.
    >> Share

  284. CHARALAMPOUS C, Doucette K, Chappell A, Vesole DH, et al
    Venetoclax-based induction therapy for primary plasma cell leukemia with high BCL-2 expression.
    Leuk Lymphoma. 2024 Aug 1:1-4. doi: 10.1080/10428194.2024.2381647.
    >> Share

    July 2024
  285. DALAL P, Dalal J
    PTCy-ATG mutually exclusive or additive? Anti-thymocyte globulin combined with post-transplantation cyclophosphamide reduce graft-versus-host disease in hematopoietic stem cell transplantation for pediatric leukemia.
    Leuk Lymphoma. 2024 Jul 31:1-2. doi: 10.1080/10428194.2024.2379976.
    >> Share

  286. CHOI YJ, Kook HW, Lee ST, Song J, et al
    The utility of next generation sequencing-based minimal residual disease monitoring in a post-myeloproliferative neoplasm acute myeloid leukemia patient: a case report.
    Leuk Lymphoma. 2024 Jul 29:1-4. doi: 10.1080/10428194.2024.2385498.
    >> Share

  287. JAIN U, Rahim F, Jain B, Tresa Mathew A, et al
    Trends in location of death for individuals with acute myeloid leukemia in the United States.
    Leuk Lymphoma. 2024 Jul 27:1-4. doi: 10.1080/10428194.2024.2382330.
    >> Share

  288. ZHANG B, Mahsoub S, Weinberg O, Germans SK, et al
    Clinicopathologic characteristics of de novo NF1-mutated acute myeloid leukemia.
    Leuk Lymphoma. 2024 Jul 27:1-4. doi: 10.1080/10428194.2024.2382329.
    >> Share

  289. SRIPORNSAWAN P, Chavananon S, Kittivisuit S, Songthawee N, et al
    Long-term survival outcome of childhood acute myeloid leukemia: a 43-year experience in Thailand, a resource-limited country.
    Leuk Lymphoma. 2024 Jul 26:1-10. doi: 10.1080/10428194.2024.2382916.
    >> Share

  290. TOHO M, Yasunaga M, Masuda Y, Shimura A, et al
    Adult T-cell leukemia-lymphoma with neurolymphomatosis successfully controlled by valemetostat: a case report and review of literature.
    Leuk Lymphoma. 2024 Jul 25:1-5. doi: 10.1080/10428194.2024.2381646.
    >> Share

  291. FANG J, Shankar N, Bao L, Haag M, et al
    Near-tetraploidy/tetraploidy acute myeloid leukemia with clinical, pathologic and molecular characteristics.
    Leuk Lymphoma. 2024 Jul 25:1-10. doi: 10.1080/10428194.2024.2382923.
    >> Share

  292. TARANTINI F, Cumbo C, Anelli L, Zagaria A, et al
    Venetoclax-based treatment in acute myeloid leukemia: an unexpected bonus on the path to allogeneic hematopoietic stem cell transplant?
    Leuk Lymphoma. 2024 Jul 23:1-12. doi: 10.1080/10428194.2024.2381649.
    >> Share

  293. MORENO-LORENZANA D, Juarez-Velazquez R, Reyes-Leon A, Martinez-Anaya D, et al
    CRLF2 and IKZF1 abnormalities in childhood hematological malignancies other than B-cell Acute Lymphoblastic Leukemia.
    Leuk Lymphoma. 2024 Jul 21:1-11. doi: 10.1080/10428194.2024.2378817.
    >> Share

  294. TRAN QUANG V, Wagner-Ballon O, Sloma I
    Predicting which subsets of patients with myelodysplastic neoplasms are more likely to progress to overt chronic myelomonocytic leukemia.
    Leuk Lymphoma. 2024 Jul 14:1-11. doi: 10.1080/10428194.2024.2378816.
    >> Share

  295. BORSOI L, Costa F, Milano C, Segantin G, et al
    Elicitation of societal preferences for chronic lymphocytic leukemia's treatments: a discrete choice experiment.
    Leuk Lymphoma. 2024 Jul 9:1-11. doi: 10.1080/10428194.2024.2374041.
    >> Share

  296. HU M, Li J, Hu T, Zhang Z, et al
    Anti-thymocyte globulin combined with post-transplantation cyclophosphamide reduce graft-versus-host disease in hematopoietic stem cell transplantation for pediatric leukemia.
    Leuk Lymphoma. 2024 Jul 7:1-10. doi: 10.1080/10428194.2024.2376179.
    >> Share

  297. DIEBOLD K, Bourne G, Espinoza-Gutarra M, Al-Kadhimi Z, et al
    Idarubicin and cytarabine with and without midostaurin for FLT3-mutated acute myeloid leukemia.
    Leuk Lymphoma. 2024 Jul 7:1-3. doi: 10.1080/10428194.2024.2373324.
    >> Share

  298. TORELI ACM, Miranda-Galvis M, Sharara M, Addas-Carvalho M, et al
    Exploring SARS-CoV-2 infection and vaccine-induced immunity in chronic myeloid leukemia patients: insights from real-world data in Brazil and the United States.
    Leuk Lymphoma. 2024 Jul 5:1-10. doi: 10.1080/10428194.2024.2367057.
    >> Share

  299. LAVIE G, Tadmor T
    It's time to change the standard of care for hairy cell leukemia?!
    Leuk Lymphoma. 2024 Jul 5:1-3. doi: 10.1080/10428194.2024.2371497.
    >> Share

  300. ALHAJAHJEH A, Bewersdorf JP, Bystrom RP, Zeidan AM, et al
    Acute myeloid leukemia (AML) with chromosome 3 inversion: biology, management, and clinical outcome.
    Leuk Lymphoma. 2024 Jul 4:1-11. doi: 10.1080/10428194.2024.2367040.
    >> Share

  301. TAKIZAWA J, Teshima T, Ennishi D, Ichikawa S, et al
    Safety and efficacy of acalabrutinib and obinutuzumab in treatment-naive chronic lymphocytic leukemia: a Japanese phase 1 study.
    Leuk Lymphoma. 2024 Jul 1:1-9. doi: 10.1080/10428194.2024.2370436.
    >> Share

  302. SURESH D, Rastogi P, Bal A, Lad D, et al
    Bridging the gap: understanding contemporary autopsies in acute leukemia by comparing ante-mortem and post-mortem profiles.
    Leuk Lymphoma. 2024 Jul 1:1-16. doi: 10.1080/10428194.2024.2372408.
    >> Share

  303. GOERGEN E, Al-Sawaf O
    The prognostic significance of genomic complexity in patients with CLL.
    Leuk Lymphoma. 2024;65:873-881.
    >> Share

    June 2024
  304. ANDERSON LJ, Girguis M, Kim E, Shewale J, et al
    A temporal and multinational assessment of acute myeloid leukemia (AML) cancer incidence, survival, and disease burden.
    Leuk Lymphoma. 2024 Jun 27:1-10. doi: 10.1080/10428194.2024.2360536.
    >> Share

  305. YU G, Zhang W, Basyal M, Nishida Y, et al
    The multi-kinase inhibitor CG-806 exerts anti-cancer activity against acute myeloid leukemia by co-targeting FLT3, BTK, and aurora kinases.
    Leuk Lymphoma. 2024 Jun 13:1-16. doi: 10.1080/10428194.2024.2364839.
    >> Share

  306. ABE C, Keto J, Lilja M, Konradsen M, et al
    Cytarabine dose intensification improves survival in older patients with secondary/high-risk acute myeloid leukemia in matched real-world versus clinical trial data.
    Leuk Lymphoma. 2024 Jun 11:1-9. doi: 10.1080/10428194.2024.2363430.
    >> Share

  307. BHATLA T, Cooper S, Hogan LE
    Low-risk relapsed acute lymphoblastic leukemia in children and young adults: what have we learnt and what's next?
    Leuk Lymphoma. 2024 Jun 11:1-7. doi: 10.1080/10428194.2024.2362408.
    >> Share

  308. CHANG JE, Wang T, Kim K, Folstad M, et al
    Maintenance low-dose fixed duration lenalidomide and rituximab following bendamustine and rituximab induction in previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma.
    Leuk Lymphoma. 2024 Jun 10:1-9. doi: 10.1080/10428194.2024.2360535.
    >> Share

  309. SHORT NJ, Kantarjian H, Jabbour E
    Advances in the treatment of adults with newly diagnosed B-cell acute lymphoblastic leukemia: the role of frontline immunotherapy-based regimens.
    Leuk Lymphoma. 2024 Jun 8:1-13. doi: 10.1080/10428194.2024.2364043.
    >> Share

  310. GERA K, Cline C, Al-Mansour Z, Medvec A, et al
    A phase ib clinical trial of oral ciprofloxacin and etoposide in subjects with resistant acute myeloid leukemia.
    Leuk Lymphoma. 2024 Jun 6:1-9. doi: 10.1080/10428194.2024.2361111.
    >> Share

  311. SHOUSE G, Chen L, Siddiqi T, Muir A, et al
    A phase II study of induction followed by intermittent duvelisib dosing in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
    Leuk Lymphoma. 2024 Jun 5:1-4. doi: 10.1080/10428194.2024.2361841.
    >> Share

  312. FREI CR, Ryan K, Obodozie-Ofoegbu GO, Moore AM, et al
    Shift in first-line therapies for United States Veterans Affairs (VA) patients with chronic lymphocytic leukemia (CLL).
    Leuk Lymphoma. 2024 Jun 4:1-4. doi: 10.1080/10428194.2024.2360526.
    >> Share

  313. FANG J, Bosma G, Aisner D, McMahon C, et al
    White blood cell count nadir to zero following intensive chemotherapy as a predictive factor for patients with acute myeloid leukemia.
    Leuk Lymphoma. 2024;65:800-807.
    >> Share

    May 2024
  314. MINNEMA MC, Yin X, Davi R, Keeping S, et al
    Outcomes of patients aged >/=26 years with relapsed or refractory B-cell acute lymphoblastic leukemia in ZUMA-3 and historical trials.
    Leuk Lymphoma. 2024 May 24:1-10. doi: 10.1080/10428194.2024.2353877.
    >> Share

  315. BELDZINSKA-GADEK K, Zarzycka E, Pastuszak K, Borman K, et al
    Immune escape of B-cell lymphoblastic leukemic cells through a lineage switch to acute myeloid leukemia.
    Leuk Lymphoma. 2024 May 22:1-11. doi: 10.1080/10428194.2024.2351194.
    >> Share

  316. ZHENG Y, Li J, Wen H, Weng K, et al
    Experience in improving treatment outcomes for childhood acute lymphoblastic leukemia: real-world results for a province in China, 2011-2020.
    Leuk Lymphoma. 2024 May 20:1-11. doi: 10.1080/10428194.2024.2350665.
    >> Share

  317. MARVIN-PEEK J, Jen WY, Kantarjian HM, McCue D, et al
    Long-term results of the sequential combination of cladribine and rituximab in Hairy cell leukemia.
    Leuk Lymphoma. 2024 May 15:1-10. doi: 10.1080/10428194.2024.2349700.
    >> Share

  318. DESPAS F, Chaouki M, de Barros S, Bonneau B, et al
    Pharmacokinetics of idelalisib in chronic lymphocytic leukemia and follicular lymphoma disclose better outcomes for patients with lower exposure.
    Leuk Lymphoma. 2024 May 15:1-3. doi: 10.1080/10428194.2024.2353330.
    >> Share

  319. WANG CP, Ferreira JE, Placek A, Aguayo-Hiraldo P, et al
    A de novo germline RUNX1 variant preceding development of concurrent T-lymphoblastic leukemia and myelodysplastic syndrome.
    Leuk Lymphoma. 2024 May 11:1-5. doi: 10.1080/10428194.2024.2347577.
    >> Share

  320. HUNTINGTON SF, Cheng WY, Sarpong EM, Leng S, et al
    Real-world patterns and sequences of targeted therapy use in chronic lymphocytic leukemia and small lymphocytic lymphoma in the United States: a longitudinal study.
    Leuk Lymphoma. 2024 May 2:1-11. doi: 10.1080/10428194.2024.2331631.
    >> Share

  321. ROGERS KA, Thompson PA
    Pairing obinutuzumab with venetoclax in relapsed CLL.
    Leuk Lymphoma. 2024;65:543-545.
    >> Share

  322. GARCIAZ S, Berton G, Hospital MA, Guille A, et al
    Long-term survival of NPM1 AML treated with intensive chemotherapy with extensive molecular data available.
    Leuk Lymphoma. 2024;65:700-703.
    >> Share

  323. OKABE S, Moriyama M, Gotoh A
    Effects of bortezomib on ponatinib-resistant Philadelphia chromosome-positive cells.
    Leuk Lymphoma. 2024;65:696-699.
    >> Share

  324. FATIMA N, Shen Y, Crassini K, Burling O, et al
    The CIpP activator, TR-57, is highly effective as a single agent and in combination with venetoclax against CLL cells in vitro.
    Leuk Lymphoma. 2024;65:585-597.
    >> Share

    April 2024
  325. NESR G, Claudiani S, Milojkovic D, Innes A, et al
    Effect of tyrosine kinase inhibitors on male fertility in patients with chronic phase chronic myeloid leukemia.
    Leuk Lymphoma. 2024 Apr 23:1-6. doi: 10.1080/10428194.2024.2343758.
    >> Share

  326. STEMPEL JM, Shallis RM, Wong R, Podoltsev NA, et al
    Challenges in management of older patients with chronic myeloid leukemia.
    Leuk Lymphoma. 2024 Apr 23:1-14. doi: 10.1080/10428194.2024.2342559.
    >> Share

  327. BEWERSDORF JP, Patel KK, Shallis RM, Podoltsev NA, et al
    Cost-effectiveness of adding quizartinib to induction chemotherapy for patients with FLT3-mutant acute myeloid leukemia.
    Leuk Lymphoma. 2024 Apr 22:1-9. doi: 10.1080/10428194.2024.2344052.
    >> Share

  328. FLECK C, Karabinos A, Cook A, Moore DC, et al
    Evaluation of safety outcomes with transitioning obinutuzumab from standard rate to short duration infusion in patients with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2024 Apr 22:1-2. doi: 10.1080/10428194.2024.2341999.
    >> Share

  329. TINAJERO J, Ngo D, Zhang J, Tsai NC, et al
    High remission rates and transition to allogeneic transplant in older patients with newly diagnosed FLT-3 mutated acute myelogenous leukemia with midostaurin plus intensive chemotherapy.
    Leuk Lymphoma. 2024 Apr 18:1-4. doi: 10.1080/10428194.2024.2332506.
    >> Share

  330. STEIN EM, Fathi AT, Harb WA, Colak G, et al
    Results from phase 1 of the MANIFEST clinical trial to evaluate the safety and tolerability of pelabresib in patients with myeloid malignancies.
    Leuk Lymphoma. 2024;65:503-510.
    >> Share

  331. PARVIZ M, Agius R, Rotbain EC, Vainer N, et al
    Identifying CLL patients at high risk of atrial fibrillation on treatment using machine learning.
    Leuk Lymphoma. 2024;65:449-459.
    >> Share

  332. ALDOSS I, Clark MC, Wang X, Forman SJ, et al
    Leveraging CD19CAR T cells early in the treatment of older patients with B-ALL: are we there yet?
    Leuk Lymphoma. 2024;65:440-448.
    >> Share

    March 2024
  333. CORTES J, Jonas BA, Schiller G, Mims A, et al
    Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (mIDH1) acute myeloid leukemia (AML).
    Leuk Lymphoma. 2024 Mar 27:1-8. doi: 10.1080/10428194.2024.2333451.
    >> Share

  334. MATTHEWS A, Fenu E, Skuli SJ, Harris JC, et al
    Immunohistochemistry-based detection of TP53 mutations in acute myeloid leukemia: a promising high sensitivity diagnostic approach.
    Leuk Lymphoma. 2024 Mar 27:1-4. doi: 10.1080/10428194.2024.2332505.
    >> Share

  335. ABDALLAH AM, Hafez H, Madney Y, Ahmed S, et al
    Predictive value of early molecular response to tyrosine kinase inhibitors in pediatric patients with chronic myeloid leukemia.
    Leuk Lymphoma. 2024 Mar 21:1-4. doi: 10.1080/10428194.2024.2331625.
    >> Share

  336. LACZKO D, Poveda-Rogers C, Matthews AH, Snaith O, et al
    RAD21 mutations in acute myeloid leukemia.
    Leuk Lymphoma. 2024 Mar 20:1-7. doi: 10.1080/10428194.2024.2328233.
    >> Share

  337. ZHU J, Xu M, Ru Y, Gong H, et al
    Comparison of valganciclovir versus foscarnet for the treatment of cytomegalovirus viremia in adult acute leukemia patients after allogeneic hematopoietic cell transplantation.
    Leuk Lymphoma. 2024 Mar 12:1-9. doi: 10.1080/10428194.2024.2321322.
    >> Share

    February 2024
  338. NASKAR S, Paul T, Kulkarni JD, Anand KC, et al
    TCF3::PBX1 fusion pediatric B acute lymphoblastic leukemia in disguise behind the eyes - an unusual clinicopathologic presentation with hyperdiploid clone.
    Leuk Lymphoma. 2024 Feb 26:1-5. doi: 10.1080/10428194.2024.2320827.
    >> Share

  339. HOFER KD, Buhler MM, Roncador M, Rechsteiner M, et al
    Mutational patterns in therapy-related acute lymphoblastic leukemia subgroups: one step closer to unveiling the genetic odyssey.
    Leuk Lymphoma. 2024 Feb 22:1-8. doi: 10.1080/10428194.2024.2315171.
    >> Share

  340. MURPHY L, Siegele B, Carstens B, Hartman L, et al
    A pediatric case of KMT2A-rearranged B-lymphoblastic lymphoma treated with high-risk therapy.
    Leuk Lymphoma. 2024 Feb 19:1-5. doi: 10.1080/10428194.2024.2315159.
    >> Share

  341. TANG K, Lipton JH
    Stem cell allografting for chronic Myeloid leukemia in the tyrosine kinase era - forgotten but not gone.
    Leuk Lymphoma. 2024 Feb 9:1-10. doi: 10.1080/10428194.2024.2313626.
    >> Share

  342. YARED JA, Lee TY, Cooke CE, Johnson A, et al
    Disparity in treatment patterns among Medicare beneficiaries diagnosed with chronic lymphocytic leukemia: an analysis of patient and contextual factors.
    Leuk Lymphoma. 2024 Feb 7:1-11. doi: 10.1080/10428194.2024.2310150.
    >> Share

  343. EL-ASHWAH S, Salmanton-Garcia J, Bilgin YM, Itri F, et al
    The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey.
    Leuk Lymphoma. 2024;65:199-208.
    >> Share

  344. JOHNSON SM, Haberberger J, Galeotti J, Ramkissoon L, et al
    Comprehensive genomic profiling reveals molecular subsets of ASXL1-mutated myeloid neoplasms.
    Leuk Lymphoma. 2024;65:209-218.
    >> Share

    January 2024
  345. LEI MM, Sorial MN, Lou U, Yu M, et al
    Real-world evidence of obinutuzumab and venetoclax in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
    Leuk Lymphoma. 2024 Jan 31:1-7. doi: 10.1080/10428194.2024.2310144.
    >> Share

  346. NASR AA, Fund X, Barreau S, Desterke C, et al
    BIRC-3 mutated monoclonal B lymphocytosis without evolution to chronic lymphocytic leukemia (CLL).
    Leuk Lymphoma. 2024 Jan 31:1-4. doi: 10.1080/10428194.2024.2308665.
    >> Share

  347. TADMOR T, Levy Yurkovski I
    Therapy with mosunetuzumab, a bispecific antibody for relapsed/refractory hairy cell leukemia.
    Leuk Lymphoma. 2024 Jan 22:1-4. doi: 10.1080/10428194.2024.2304026.
    >> Share

  348. FU S, Alhaj Z, Huynh D
    Prevalence of primary chronic lymphocytic leukemia in the United States: a cross-sectional study using the SEER database.
    Leuk Lymphoma. 2024 Jan 22:1-2. doi: 10.1080/10428194.2023.2300714.
    >> Share

  349. BANERJI V, Aw A, Laferriere N, Abdel-Samad N, et al
    Management and use of healthcare resources in patients with chronic lymphocytic leukemia initiating venetoclax in routine clinical practice.
    Leuk Lymphoma. 2024 Jan 18:1-9. doi: 10.1080/10428194.2024.2301738.
    >> Share

  350. NGO D, Tinajero J, Li S, Palmer J, et al
    Treatment of relapsed or refractory FLT-3 acute myelogenous leukemia with a triplet regimen of hypomethylating agent, venetoclax, and gilteritinib.
    Leuk Lymphoma. 2024 Jan 2:1-6. doi: 10.1080/10428194.2023.2292473.
    >> Share

    December 2023
  351. SALTER B, Radford JM, Berg T, Leber B, et al
    The successful management of acute promyelocytic leukemia during pregnancy: a case report.
    Leuk Lymphoma. 2023 Dec 19:1-4. doi: 10.1080/10428194.2023.2295786.
    >> Share

  352. MUTTI M, Cordella S, Parisotto A, Bettelli F, et al
    Characteristics and clinical behavior of acute myeloid leukemia harboring rare non-A/B/D nucleophosmin (NPM1) gene mutation subtypes: a single-center experience and review of the literature.
    Leuk Lymphoma. 2023 Dec 19:1-5. doi: 10.1080/10428194.2023.2294695.
    >> Share

  353. WANG L, Gao L, Liang Z, Cen X, et al
    Efficacy and safety of coadministration of venetoclax and anti-fungal agents under therapeutic drug monitor in unfit acute myeloid leukemia and high-risk myelodysplastic syndrome with neutropenia: a single-center retrospective study.
    Leuk Lymphoma. 2023 Dec 9:1-10. doi: 10.1080/10428194.2023.2290465.
    >> Share

  354. JEN WY, Sasaki K, Rausch CR, DiNardo CD, et al
    Acute kidney injury in acute promyelocytic leukemia: a possible adverse effect of high dose arsenic trioxide in obese patients.
    Leuk Lymphoma. 2023 Dec 6:1-5. doi: 10.1080/10428194.2023.2290467.
    >> Share

  355. ZHANG F, Hu GH, Zhang LP, Xu LP, et al
    Outcomes of haploidentical hematopoietic stem cell transplantation with 'Beijing protocol' in pediatric myeloid neoplasms post cytotoxic therapy: a case series study.
    Leuk Lymphoma. 2023 Dec 3:1-6. doi: 10.1080/10428194.2023.2281276.
    >> Share

  356. MURTON A, Forsyth C, Ross DM, Grigg A, et al
    Significant heterogeneity in management of calreticulin-mutated essential thrombocythemia and its progression to myelofibrosis: results of a national survey.
    Leuk Lymphoma. 2023;64:2018-2025.
    >> Share

  357. STEIN EM, de Botton S, Cluzeau T, Pigneux A, et al
    Use of tamibarotene, a potent and selective RARalpha agonist, in combination with azacitidine in patients with relapsed and refractory AML with RARA gene overexpression.
    Leuk Lymphoma. 2023;64:1992-2001.
    >> Share

  358. REDD RA, Ford J, Lei M, Abramson JS, et al
    Combined analysis of the impact of second-generation BTK inhibitors on patient outcomes.
    Leuk Lymphoma. 2023;64:2296-2305.
    >> Share

  359. YANG T, Mahmood N, Goldberg B, Cevallos J, et al
    Myeloid/lymphoid neoplasm with a novel cryptic RBPMS::FGFR1 rearrangement presenting as de novo acute leukemias.
    Leuk Lymphoma. 2023;64:2338-2342.
    >> Share

  360. TOMASULO E, Paul S, Mu R, Tian X, et al
    Interruption of BTK inhibitor improves response to SARS-CoV-2 booster vaccination in patients with CLL.
    Leuk Lymphoma. 2023;64:2306-2315.
    >> Share

  361. SMITH AL, Pal D, Martinez-Rico R, Eiken AP, et al
    Preclinical activity of a novel multi-axis inhibitor in aggressive and indolent B-cell malignancies.
    Leuk Lymphoma. 2023;64:2333-2337.
    >> Share

  362. ZHANG X, Wang T, Zhang Y, Wang F, et al
    Characteristics and therapeutic approaches for patients diagnosed with T-ALL/LBL exhibiting t(8;14)(q24;q11)/TCRA/D:MYC translocation.
    Leuk Lymphoma. 2023;64:2133-2139.
    >> Share

    November 2023
  363. LAI X, Xiao J, Wang T, Hou C, et al
    Prognostic significance of persisting DNMT3A, ASXL1, and TET2 mutation burden in acute myeloid leukemia patients with allogeneic hematopoietic stem cell transplantation during complete remission.
    Leuk Lymphoma. 2023 Nov 22:1-9. doi: 10.1080/10428194.2023.2284089.
    >> Share

  364. OU J, Xu X, Deng S, Liang H, et al
    Prognostic impact of TP53 mutations in adult acute lymphoblastic leukemia treated with a pediatric-type regimen.
    Leuk Lymphoma. 2023 Nov 8:1-9. doi: 10.1080/10428194.2023.2278026.
    >> Share

  365. FATIMA N, Best OG, Belov L, Christopherson RI, et al
    The effect of HYPE knock-out on the AMPylome of human OSU-CLL leukemia cells.
    Leuk Lymphoma. 2023 Nov 7:1-8. doi: 10.1080/10428194.2023.2275530.
    >> Share

  366. KHOUDERCHAH CJ, Benitez LL, Marini BL, Fraga M, et al
    Tumor lysis syndrome in patients with acute myeloid leukemia treated with venetoclax and hypomethylating agents with or without dose ramp-up.
    Leuk Lymphoma. 2023 Nov 6:1-7. doi: 10.1080/10428194.2023.2276056.
    >> Share

  367. SASTOW D, Tatarian J, Salib C, Lin TL, et al
    Response to 'blast identification in cerebrospinal fluid specimens from patients with acute myeloid leukemia: laboratory perspectives'.
    Leuk Lymphoma. 2023 Nov 3:1-2. doi: 10.1080/10428194.2023.2274658.
    >> Share

  368. FRATER JL
    Blast identification in cerebrospinal fluid specimens from patients with acute myeloid leukemia: laboratory perspectives.
    Leuk Lymphoma. 2023 Nov 3:1-2. doi: 10.1080/10428194.2023.2273749.
    >> Share

  369. SOSNIA O, Pruszczyk K, Danecki M, Wasik-Szczepanek E, et al
    Richter transformation - retrospective treatment outcomes analysis in Polish Adult Leukemia Study Group.
    Leuk Lymphoma. 2023 Nov 3:1-12. doi: 10.1080/10428194.2023.2277140.
    >> Share

  370. TRINQUAND A, Betts DR, Harte S, Sills A, et al
    Adapted risk stratification and intensive chemotherapy abrogate the poor prognosis of pediatric B acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21 (iAMP21): a National cohort analysis.
    Leuk Lymphoma. 2023 Nov 1:1-4. doi: 10.1080/10428194.2023.2276061.
    >> Share

  371. RAMACHANDRA N, Gupta M, Schwartz L, Todorova T, et al
    Role of IL8 in myeloid malignancies.
    Leuk Lymphoma. 2023;64:1742-1751.
    >> Share

  372. ITONAGA H, Kato T, Sawayama Y, Katsuoka S, et al
    RAISING revealed a heterogenous pattern of HTLV-1 clonality after HLA-haploidentical peripheral blood stem cell transplantation for ATL.
    Leuk Lymphoma. 2023 Nov 1:1-4. doi: 10.1080/10428194.2023.2276058.
    >> Share

    October 2023
  373. MERIC N, Albayrak E, Gulbas Z, Kocabas F, et al
    MEIS inhibitors reduce the viability of primary leukemia cells and Stem cells by inducing apoptosis.
    Leuk Lymphoma. 2023 Oct 30:1-12. doi: 10.1080/10428194.2023.2275532.
    >> Share

  374. CONTRERAS YAMETTI GP, Robbins G, Chowdhury A, Narang S, et al
    SETD2 mutations do not contribute to clonal fitness in response to chemotherapy in childhood B cell acute lymphoblastic leukemia.
    Leuk Lymphoma. 2023 Oct 24:1-13. doi: 10.1080/10428194.2023.2273752.
    >> Share

  375. HUNTINGTON SF, de Nigris E, Puckett J, Kamal-Bahl S, et al
    Ibrutinib discontinuation and associated factors in a real-world national sample of elderly Medicare beneficiaries with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2023 Oct 23:1-10. doi: 10.1080/10428194.2023.2256911.
    >> Share

  376. LIAO C, Nie J, Xu XJ, Zhang JY, et al
    The effect of the plasma methotrexate concentration during high-dose methotrexate therapy in childhood acute lymphoblastic leukemia.
    Leuk Lymphoma. 2023 Oct 11:1-9. doi: 10.1080/10428194.2023.2266075.
    >> Share

  377. ZAHID MF, Kainthla R
    Sustained long-term remission with tyrosine kinase inhibitor therapy in treatment-refractory B-cell acute lymphoblastic leukemia harboring a RCSD1::ABL2 fusion gene.
    Leuk Lymphoma. 2023 Oct 9:1-5. doi: 10.1080/10428194.2023.2264428.
    >> Share

  378. GAUT D, Oliai C, Boiarsky J, Zhang S, et al
    Measurable residual disease conversion rate with consolidation chemotherapy in acute myeloid leukemia.
    Leuk Lymphoma. 2023 Oct 6:1-9. doi: 10.1080/10428194.2023.2264426.
    >> Share

  379. YASU T, Gando Y, Shirota M, Kosugi N, et al
    Association between plasma venetoclax trough levels and serum C-reactive protein levels in patients with acute myeloid leukemia treated with venetoclax plus azacitidine.
    Leuk Lymphoma. 2023 Oct 5:1-4. doi: 10.1080/10428194.2023.2264427.
    >> Share

  380. SABILE JMG, Kaempf A, Tomic K, Manu GP, et al
    A retrospective validation of the IPSS-M molecular score in primary and therapy-related myelodysplastic syndromes (MDS).
    Leuk Lymphoma. 2023;64:1689-1694.
    >> Share

  381. CHAI J, Choudhuri J, Wang Q, Fang Y, et al
    Acute myeloid leukemias with JAK2/STAT mutations are associated with PD-L1 upregulation.
    Leuk Lymphoma. 2023;64:1662-1672.
    >> Share

    September 2023
  382. LI L, Zhang R, Cao W, Bian Z, et al
    Comparative analysis of hypomethylating agents as maintenance therapy after allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Leuk Lymphoma. 2023 Sep 21:1-10. doi: 10.1080/10428194.2023.2252948.
    >> Share

  383. HUNTINGTON SF, Manzoor BS, Puckett JT, Kamal-Bahl S, et al
    Real-world adherence and discontinuation among Medicare beneficiaries initiating venetoclax vs. BTKis in relapsed/refractory chronic lymphocytic leukemia.
    Leuk Lymphoma. 2023 Sep 21:1-8. doi: 10.1080/10428194.2023.2255326.
    >> Share

  384. LESEGRETAIN A, Brunner A, Benzohra A, Fathi AT, et al
    Temporal trend in survival for chronic myelomonocytic leukemia in the US: a population-based study.
    Leuk Lymphoma. 2023 Sep 15:1-9. doi: 10.1080/10428194.2023.2252123.
    >> Share

  385. IELO C, Scalzulli E, Carmosino I, Pepe S, et al
    Validation of imatinib therapy failure score (IMTF) in chronic phase chronic myeloid leukemia in real life practice.
    Leuk Lymphoma. 2023 Sep 10:1-3. doi: 10.1080/10428194.2023.2255804.
    >> Share

  386. LA J, Lee MH, Brophy MT, Do NV, et al
    Baseline correlates of frailty and its association with survival in United States veterans with acute myeloid leukemia.
    Leuk Lymphoma. 2023 Sep 6:1-10. doi: 10.1080/10428194.2023.2254434.
    >> Share

  387. BHATNAGAR B, Zhao Q, Mims AS, Vasu S, et al
    Phase 1 study of selinexor in combination with salvage chemotherapy in Adults with relapsed or refractory Acute myeloid leukemia.
    Leuk Lymphoma. 2023 Sep 4:1-10. doi: 10.1080/10428194.2023.2253480.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016